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Introduction {#sec1}
============

Type 1 and type 2 conventional dendritic cells (cDC1s and cDC2s, respectively) and plasmacytoid DCs (pDCs) are defined by expression of cell surface markers and develop from well-known common DC and pre-cDC progenitors through the action of lineage-defining transcription factors (TFs) ([@bib13], [@bib35], [@bib39], [@bib41], [@bib73], [@bib87]). The TFs interferon regulatory factor 8 (IRF-8) and Batf3 drive the development of chemokine receptor XCR1-expressing cDC1s, which have the capacity to present and cross-present antigens to CD8^+^ T cells and are a copious source of interleukin-12 (IL-12) ([@bib6], [@bib9], [@bib28], [@bib29], [@bib30], [@bib35], [@bib93]). On the other hand, IRF4 drives the development and terminal differentiation of the CD11b^+^CD172a^+^-expressing cDC2 lineage, which is more specialized in polarizing CD4^+^ T helper (Th) cell responses and providing help to B cells ([@bib8], [@bib31], [@bib60], [@bib61], [@bib66], [@bib74], [@bib85], [@bib86], [@bib101], [@bib108]).

Many studies have dissected the antigen-presenting functions of cDC1s and cDC2s by sorting by unique surface marker expression ([@bib10], [@bib33], [@bib46], [@bib63]) or conditional inactivation of *Irf8* or *Irf4* in *Itgax*-expressing cells to target cDC1s or cDC2s, respectively ([@bib11], [@bib102], [@bib25], [@bib51], [@bib65], [@bib68], [@bib81]). However, the selectivity and validity of these approaches mainly derives from studies that have measured cell surface markers and IRF expression in the steady state without properly questioning how expression is altered by inflammation. Moreover, as soon as tissue inflammation is present, Ly6C^hi^CD11b^+^CD172a^+^ monocytes enter antigen-exposed barrier sites and lymph nodes (LNs). Monocytes can then rapidly upregulate the expression of Major Histocompatibility Complex class II (MHCII) and CD11c while downregulating expression of Ly6C. These cells are known by various names, like monocyte-derived cells (MCs), monocyte-derived DCs (moDCs), or inflammatory DCs, and can be easily confused with CD11b^+^CD172a^+^ cDC2s, particularly because they also express CD11b, CD172a, and intermediate amounts of IRF4 ([@bib64], [@bib70], [@bib75], [@bib82]). Although MafB lineage tracing studies suggest that MCs are much more related to macrophages than DCs, they perform well in *ex vivo* antigen presentation assays, leading to their classification as professional antigen-presenting cells (APCs) and their designation as moDCs ([@bib21], [@bib56], [@bib57], [@bib64], [@bib84], [@bib109]). Although cDCs readily migrate to draining nodes, MCs are usually less migratory.

It is now assumed that MCs and macrophages can be readily discriminated from cDCs based on their surface expression of the high-affinity Fc gamma receptor CD64, by staining with the MAR-1 clone of the anti-FcεRI antibody, or by expression of Tyrosine-protein kinase Mer (MerTK) and CD88 ([@bib32], [@bib45], [@bib78], [@bib82], [@bib95], [@bib96], [@bib98]). However, CD64 has been reported to also identify a subset of kidney cDCs in the steady state ([@bib88]). Understanding which APCs express Fc receptors is important because uptake of antigen via convalescent serum or immune complexes is an effective way of targeting antigen to APCs during an ongoing primary or recall immune response ([@bib40], [@bib63]).

We found significant overlap in marker and TF expression in cDCs and MCs. *Bona fide* inflammatory cDC2s (inf-cDC2s) acquired characteristics traditionally defining cDC1 and macrophages in a type I interferon (IFN)-dependent manner. By also acquiring shared functions such as IL-12 production and Fc receptor-mediated antigen uptake, inf-cDC2s optimally primed CD4^+^ and CD8^+^ T cell-mediated immunity to respiratory virus infection.

Results {#sec2}
=======

CD26^+^CD64^+^ MAR-1^+^ DCs Accumulate in Tissues and LNs of Virus-Infected Mice {#sec2.1}
--------------------------------------------------------------------------------

DC subsets and CD11c^+^MHCII^+^ MCs were studied in naive (mock-infected) lungs and lungs of mice infected with the single-stranded RNA virus pneumonia virus of mice (PVM), a virus closely related to human respiratory syncytial virus (RSV), which causes a severe acute respiratory distress syndrome (ARDS)-like disease ([@bib103]). *Bona fide* cDCs were separated from MCs by surface staining for CD26 and CD64, respectively, whereas XCR1 and CD172a (Sirpα) were used to separate cDC1s from cDC2s, respectively ([@bib41]). We additionally stained cells with the antibody MAR-1 raised against FcεRI, also known to bind CD64 and FcγRIV on DCs and shown previously to mark inflammatory DCs ([@bib36], [@bib45], [@bib98]).

In mock-infected mice, CD26^+^ XCR1^+^ cDC1s and CD172a^+^ cDC2s made up around one- and two-thirds of the lung cDC population, respectively, whereas CD26^lo^CD172a^+^CD64^hi^ MCs were barely recovered in the MHCII^+^CD11c^+^ cell population ([Figure 1](#fig1){ref-type="fig"} A; summarized in [Figure 1](#fig1){ref-type="fig"}C). At 8 days post infection (dpi) with PVM ([Figure 1](#fig1){ref-type="fig"}B), when the viral load is highest in this model, total lung MHCII^+^CD11c^+^ cells had expanded greatly. The proportion of cDC1s and cDC2s in this cell fraction had decreased, whereas the proportion of MCs was significantly increased ([Figure 1](#fig1){ref-type="fig"}C), and expression of MAR-1 was upregulated ([Figure 1](#fig1){ref-type="fig"}D). Another DC population appeared, expressing CD26 and CD172a like cDC2s but was marked by expression of CD64 and MAR-1 ([Figures 1](#fig1){ref-type="fig"}B and 1D), which we termed CD26^+^CD64^+^MAR-1^+^ DCs. The intensity of CD64 staining on CD26^+^CD64^+^ DCs was between that of cDCs and that of MCs ([Figure 1](#fig1){ref-type="fig"}D), but without use of CD26, it would be very difficult to separate these cells from MCs. Following viral clearance, CD26^+^CD64^+^MAR-1^+^ DCs were no longer identifiable in the lung, but cDC and MC numbers remained elevated at 18 dpi ([Figure 1](#fig1){ref-type="fig"}C).Figure 1CD26^+^MAR-1^+^CD64^+^ DCs Are Induced after Pneumovirus Infection(A and B) Gating strategy of lung DC subsets pre-gated on live CD3^−^CD19^−^ non-autofluorescent cells in mock-infected controls (A) or 8 dpi with PVM (B). cDC1s are shown in blue, cDC2s in green, MAR-1^+^ DCs in red, and MCs in orange gates. These colored gates are maintained throughout the manuscript.(C) Kinetics of different lung DC subset numbers upon PVM infection (left panel) and pie charts depicting relative distribution of DC subsets in the lung upon mock or 8 dpi PVM infection (right panel) (see also [Figure S1](#mmc1){ref-type="supplementary-material"}A). Error bars indicate ± SEM.(D) Surface expression of CD64 and MAR-1 on different DC subsets in the lung 8 dpi with PVM.(E and F) Gating strategy of migratory MHCII^hi^ DC subsets in MLNs pre-gated on live CD3^−^CD19^−^ cells in mock-infected controls (E) or 8 dpi with PVM (F).(G) Kinetics of different migratory DC subset numbers in MLNs upon PVM infection (left panel) and pie charts depicting relative distribution of DC subsets in MLNs upon mock or 8 dpi PVM infection (right panel) (see also [Figure S1](#mmc1){ref-type="supplementary-material"}B).(H) Surface expression of CD64 and MAR-1 on different DC subsets in MLN 8 dpi with PVM.(I) CD45.1.2 monocytes were sorted from eFl450^+^ cell tracker-labeled BM and transferred intravenously (i.v.) into CD45.2 *Ccr2*^−/−^ recipient mice at 1 dpi with IAV. Four days later, donor cells were identified in the lungs and MLNs (see also [Figures S1](#mmc1){ref-type="supplementary-material"}C--S1H).(J) Distribution of different DC subsets in the endogenous population (white) and adoptively transferred monocyte-derived population (black) in the lungs (top panel) and MLNs (bottom panel).(K) Pre-cDCs were sorted from eFl450^+^ CellTrace™ Violet (CTV)-labeled BM from FLT3L-treated CD45.2 WT mice and transferred i.v. into CD45.1.2 WT mice at 1 dpi with IAV. Four days later, donor cells were identified in the lungs and MLNs (see also [Figures S1](#mmc1){ref-type="supplementary-material"}C--S1F).(L) Distribution of different DC subsets in the endogenous population (white) and adoptively transferred pre-cDC-derived population (black) in the lungs (top panel) and MLNs (bottom panel).(M) Histograms showing surface expression of commonly used DC and macrophage markers on different DC subsets in the lungs and MLNs 8 dpi with PVM.(A--H) Data are representative of at least 2 or 3 independent experiments with 4--6 mice per group. The size of the pie chart is proportional to the absolute number of DCs in the lungs (C) or MHCII^hi^ DCs in MLNs (G).(I--L) Data pooled from 2 independent experiments (circles and squares, n = 5 in total), analyzed with a two-way ANOVA with Sidak correction for multiple comparisons. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant.

The same gating strategy was applied to the migratory MHCII^hi^ DCs in lung draining mediastinal LNs (MLNs) ([Figures 1](#fig1){ref-type="fig"}E and 1F). In mock-infected mice, cDC2s made up the highest fraction of MLN migratory DCs ([Figures 1](#fig1){ref-type="fig"}E and 1G). At 8 dpi, there was a robust increase in cDC1s and cDC2s and a substantial population of CD26^+^CD64^+^ DCs, representing more than half of the total DC population in the MLNs. These CD26^+^MHCII^+^CD11c^+^ cells expressed CD64 and MAR-1 at an intensity comparable with lung equivalents ([Figures 1](#fig1){ref-type="fig"}F, 1D, and 1H) and were no longer detectable in MLNs following recovery from viral infection ([Figure 1](#fig1){ref-type="fig"}G). Despite their accumulation in the lungs, CD26^lo^CD64^hi^ MCs did not accumulate in MLNs ([Figures 1](#fig1){ref-type="fig"}E and 1F). Similar changes occurred in the lungs and LNs of mice infected with mild influenza A virus (IAV; strain X31) but with more rapid kinetics ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). Thus, respiratory viral infection induces a population of CD26^+^ DCs that express CD64 and MAR-1, usually found on MCs and macrophages.

CD26^+^CD64^+^MAR-1^+^ DCs Are *Bona Fide* cDC2s {#sec2.2}
------------------------------------------------

We next questioned whether the CD26^+^CD64^+^MAR-1^+^ DC population was of monocyte or pre-cDC origin. Monocytes were sorted from the bone marrow (BM) of CD45.1 wild-type mice and transferred into virus-infected CD45.2 *Ccr2* ^−/−^ mice. Four days after monocyte transfer, when viral titers are maximal in the IAV model ([@bib33]), the transferred cells were present exclusively in the lung MC gate ([Figure 1](#fig1){ref-type="fig"}I). MCs could not be recovered in MLNs, showing lack of migratory capacity ([Figures 1](#fig1){ref-type="fig"}I and 1J). Conversely, sorted CD45.2 BM pre-cDCs gave rise to cDC1s and cDC2s 4 days after transfer, but not to the CD64^hi^MAR-1^+^ MC population ([Figures 1](#fig1){ref-type="fig"}K and 1L). Pre-cDCs also gave rise to the MAR-1^+^CD64^+^ DC population in the lung and MLNs, demonstrating these cells to be genuine conventional DCs with a characteristic capacity to migrate to LNs ([Figures 1](#fig1){ref-type="fig"}K and 1L).

Conventional DCs typically depend on Flt3 ligand, and virus-infected *Flt3l* ^−/−^ mice had reduced numbers of all cDC subsets, including MAR-1^+^ DCs ([Figures S1](#mmc1){ref-type="supplementary-material"}C--S1F). Granulocyte-macrophage colony-stimulating factor (GM-CSF) acting on Csf-2r has been shown to play a cell-intrinsic pro-survival role in resident cDC homeostasis *in vivo* ([@bib37]). In wild-type (WT):*Csf2rb* ^−/−^ chimeras, Csf2rb signaling was, however, not intrinsically required for generation of MAR-1^+^ DCs and MCs ([Figure S1](#mmc1){ref-type="supplementary-material"}I). Dependency on the chemokine receptor CCR2 is widely used to define monocyte descent ([@bib91]), but it has been shown that subtypes of tissue CD11b^+^cDC2s also depend on CCR2 ([@bib79], [@bib89]). In WT:*Ccr2* ^−/−^ chimeras infected with the virus, cDC1s derived equally well from both donors, whereas MCs were generated preferentially from the WT donor component. MAR-1^+^CD11b^+^ cDCs had an intermediate dependence on CCR2 ([Figures S1](#mmc1){ref-type="supplementary-material"}G and S1H).

Compared with MCs, pre-cDC-derived MAR-1^+^ DCs expressed higher amounts of MHCII and CD26 protein ([Figure 1](#fig1){ref-type="fig"}M). In addition, CX3CR1 and CD88 were exclusively expressed by MCs ([@bib78]). Ly6C has often been used to distinguish cDC2s from MCs ([@bib33], [@bib36], [@bib44]). However, both inf-cDC2s and MCs expressed this marker ([Figure 1](#fig1){ref-type="fig"}M). In the lungs, CD209a Dendritic cell-specific ICAM-3-grabbing non-integrin (DC-SIGN) was expressed by inf-cDC2s and MCs despite earlier reports of MC exclusivity ([@bib21]). CD301b expression was only found on a fraction of cDC2s ([@bib31], [@bib61]).

Thus, in virally infected tissues, CD26^+^CD64^+^MAR-1^+^ DCs are pre-cDC-derived cells that express CD172a and CD11b but not XCR1, CD103, or CD88, identifying them as a subset of cDC2s with great potential to migrate to draining MLNs under conditions of inflammation. We therefore propose to call these cells inf-cDC2s.

Inf-cDC2s Present Antigens to CD4^+^ and CD8^+^ T Cells {#sec2.3}
-------------------------------------------------------

We created mice transgenic for a T cell receptor (TCR) recognizing a Major Histocompatibility Complex class I (MHCI)-restricted (N~339--347~) or MHCII-restricted (M~37-47~), PVM-derived T cell epitope by CD8^+^ and CD4^+^ T cells, respectively ([Figures S1](#mmc1){ref-type="supplementary-material"}K--S1P; [@bib103], [@bib107]). After 4 days of co-culture, cDC2s retrieved from MLNs at 8 dpi were more efficient in inducing virus-specific CD4^+^ T cell proliferation compared with cDC1s ([Figure 2](#fig2){ref-type="fig"} A). Inf-cDC2s induced the highest degree of CD4^+^ T cell proliferation ([Figures 2](#fig2){ref-type="fig"}A--2C), whereas cDC1s were superior in inducing proliferation of CD8^+^ T cells. Inf-cDC2s performed better than their classical cDC2 counterparts in stimulating CD8^+^ T cell immunity ([Figures 2](#fig2){ref-type="fig"}B and 2C). IFN-γ was produced in much larger quantities when CD4^+^ T cells were co-cultured with inf-cDC2s compared with cDC2s or cDC1s ([Figure 2](#fig2){ref-type="fig"}D). In contrast, IFN-γ production by CD8^+^ T cells was higher upon stimulation with cDC1s compared with cDC2s, but again, inf-cDC2s were more potent in inducing IFN-γ production from dividing CD8^+^ T cells ([Figure 2](#fig2){ref-type="fig"}D). MCs that were sorted from the lungs and carefully separated from inf-cDC2s could not induce proliferation of naive CD4^+^ or CD8^+^ T cells whereas lung inf-cDC2s readily did ([Figure 2](#fig2){ref-type="fig"}E). However, when exogenous preprocessed peptide was added to MCs, they readily induced proliferation ([Figure 2](#fig2){ref-type="fig"}E). Thus, inf-cDC2s, which represent the dominant DC population in lung-draining LNs at the peak of PVM infection, can optimally prime CD4^+^ and CD8^+^ T cell responses to virus.Figure 2Activated inf-cDC2s Share Characteristics with cDC1 and MC Subsets(A and B) Proliferation profile of CTV-labeled CD4^+^ (A) and CD8^+^ (B) PVM-specific TCR transgenic T cells cocultured for 4 days with different migratory cDC subsets sorted from 4--6 pooled MLNs 8 dpi with PVM (see also [Figures S1](#mmc1){ref-type="supplementary-material"}K--S1P).(C) Number of divided CD4^+^ and CD8^+^ PVM TCR transgenic T cells cocultured for 4 days with different migratory cDC subsets sorted from MLNs 8 dpi with PVM relative to the cDC2 subset, which is set to 0. Error bars represent 95% confidence intervals. Data were pooled from 3 independent experiments (n = 5--7).(D) IFN-γ measured in supernatants of cocultured CD4^+^ and CD8^+^ PVM TCR transgenic T cells for 4 days with different MLN-derived cDC subsets sorted 8 dpi with PVM. Data are representative of 3 independent experiments. Error bars indicate ± SEM. Mann-Whitney U test; ^∗^p \< 0.05, ^∗∗^p \< 0.01.(E) Proliferation profile of CTV-labeled CD4^+^ and CD8^+^ PVM TCR transgenic T cells cocultured for 4 days with T cells alone, inf-cDC2s, or MCs sorted from 3 pooled lungs 8 dpi with PVM. For peptide controls, 1 μg/mL of CD4^+^ (M37--M47) or CD8^+^ (N339--N347) immunodominant epitope was added *ex vivo*.(F--H) Percentage of CD86-expressing (F) and CCR7-expressing (G) and IL-12-producing (H) lung or migratory DC subsets in MLNs upon mock infection (white circles) or 10 dpi with PVM (black dots). For IL-12 staining, samples were restimulated *ex vivo* for 6 h. Data are representative of 2 independent experiments with 3--6 mice per group, analyzed with a two-way ANOVA with Sidak correction for multiple comparisons. Error bars indicate ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant. (see also [Figure S1](#mmc1){ref-type="supplementary-material"}J).(I--K) To visualize DEG between DC subsets sorted from the lungs 4 dpi after mock (I) and IAV infection (J) and those induced in inf-cDC2s (K), each gene was plotted in a hexagonal triwise diagram in which the direction of a point represents the relative higher expression in one or two populations, whereas the distance from the origin represents the magnitude of expression. Genes that are 32-fold or more differentially expressed are plotted on the outer grid line. Genes represented by gray dots in the center of the triwise plot are not differentially expressed (see also [Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D).(L) MAR-1 and CD64 staining of live CD3^−^CD19^−^MHCII^+^CD11c^+^CD172a^+^ cells 8 dpi with PVM in the lungs and MLNs of WT, *Fcer1a*^*−/−*^, and *Fcer1g*^*−/−*^ mice.(M) Proliferation profile of CTV-labeled CD4^+^ and CD8^+^ PVM TCR transgenic T cells cocultured for 4 days with different migratory cDC subsets sorted from 4 pooled MLNs 8 dpi with PVM from mice that received mock (white) or PVM (gray) IS i.t. 6 dpi.(N) Absolute number IFNγ^+^ CD4^+^ and CD8^+^ PVM TCR transgenic T cells cocultured for 4 days with different migratory cDC subsets sorted from 4 pooled MLNs 8 dpi with PVM from mice that received mock (white) or PVM (gray) IS i.t. 6 dpi. Two-way ANOVA with Sidak correction for multiple comparisons. Error bars indicate ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant. (see also [Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B).(O and P) MAR-1 and CD64 staining of live CD3^−^CD19^−^MHCII^+^CD11c^+^CD11b^+^ cells (O) 8 dpi with PVM in lungs of mice treated i.t. at 6 dpi with 50 μg Alexa Fluor 647 (AF647)-labeled OVA administered alone (left panel) or as OVA-AF647-IgG2c-IC (right panel) and the respective uptake of OVA-AF647 by these cells (P) (see also [Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D).

Inf-cDC2s Share Characteristics with cDC1s and MCs {#sec2.4}
--------------------------------------------------

In PVM-infected mice, inf-cDC2s expressed significantly higher amounts of the DC maturation marker CD86 in the lungs and MLNs compared with cDC1s, cDC2s, and MCs ([Figure 2](#fig2){ref-type="fig"}F). Upon activation, antigen-bearing cDCs migrate to MLNs in a CCR7-dependent manner ([@bib48], [@bib105]). Surface CCR7 expression was induced by infection on cDC1s, cDC2s and inf-cDC2s but not MCs ([Figure 2](#fig2){ref-type="fig"}G), and CCR7 was required for migration of inf-cDC2s to MLNs (data not shown). In steady-state mice, IL-12 is typically produced by the cDC1 subset ([@bib30]). Upon virus infection, however, lung and MLN inf-cDC2s gained enhanced capacity to produce IL-12 compared with cDC2s after 6 h of *ex vivo* restimulation, to a degree comparable with cDC1s ([Figure 2](#fig2){ref-type="fig"}H), explaining why inf-cDC2s were good inducers of IFN-γ production in CD4^+^ and CD8^+^ T cells ([Figure 2](#fig2){ref-type="fig"}D; [Figure S1](#mmc1){ref-type="supplementary-material"}J).

We next performed a RNA microarray analysis on sorted lung APC subsets to study which other features might be shared between inf-cDC2s, cDC1s, and MCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In mock-infected mice, *Xcr1*, *Clec9a*, *Cadm1*, and *Irf8* were highly specific for cDC1s and *Mertk*, *Emr1* (F4/80), and *Fcgr1* (CD64) for MCs ([Figure 2](#fig2){ref-type="fig"}I). No cDC2-specific genes could be defined because most genes were shared with cDC1s (*Dpp4* \[CD26\] and *Zbtb46*) or MCs (*Sirpa*, *Itgam*, *Csfr1*, and *Clec4a3*). Upon infection, a small fraction of the genes encoding for (surface) markers remained cDC1 specific (e.g., *Xcr1*, *Cadm1*, *Clec9a*, *Gcsam*, *Zdhhc2*, *Tlr3*, and *Itgae*) or MC specific (e.g., *Mertk*, *Mafb*, and *Emr1*) ([Figure 2](#fig2){ref-type="fig"}J; [Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D). As for cDC2s in the steady state, there were no genes specific to inf-cDC2s. All genes that were upregulated in inf-cDC2s compared with steady-state cDC2s were shared with cDC1s (e.g., *Irf8*, *Il12b*, *Il15*, *Cd80*, *Cd86*, and *Tnfrsf4*), MCs (e.g., *Fcgr1* and *Tlr7*), or both subsets ([Figure 2](#fig2){ref-type="fig"}K; [Figures S2](#mmc1){ref-type="supplementary-material"}B--S2D). Thus, inf-cDC2s induced upon virus infection were activated cDC2s that acquired a hybrid phenotypic, functional, and transcriptomic identity with characteristics of cDC1s and MCs ([Figures 2](#fig2){ref-type="fig"}A--2K; [Figures S2](#mmc1){ref-type="supplementary-material"}A--S2D).

Inf-cDC2s Internalize Antigen via Activating Fc Receptors {#sec2.5}
---------------------------------------------------------

Although *Fcgr1* and *Fcer1g* were clearly shared between inf-cDC2s and MCs ([Figures 2](#fig2){ref-type="fig"}I and 2J), we did not detect *Fcer1a*, coding for the high-affinity IgE receptor FcεRIα recognized by the MAR-1 antibody on mast cells and basophils. In addition, MAR-1 staining was intact in inf-cDCs of *Fcer1a* ^−/−^ virus-infected mice ([Figure 2](#fig2){ref-type="fig"}L) and abolished in *Fcer1g* ^−/−^ mice ([Figure 2](#fig2){ref-type="fig"}L). Thus, as reported previously ([@bib98]), MAR-1 recognizes an unknown epitope of an activating Fc receptor on inf-cDC2s and MCs. Because activating Fc receptors like CD64 and CD16b (FcγRIV) can target antigens to macrophages and DCs via binding surface immunoglobulin G (IgG) or uptake of immune complexes ([@bib40], [@bib63]), we next tested whether this would be a specialized function of inf-cDC2s. Heat-inactivated convalescent immune serum (IS) from PVM-infected mice (PVM-IS, obtained at 15 dpi) or control serum from mock-infected mice was transferred to another cohort of infected mice at 6 dpi, and DC subsets were sorted from MLNs 36 h later. Compared with mock serum, PVM-IS transfer led to enhanced capacity of inf-cDC2s to present antigen to CD4^+^ T cells, which led to higher T cell division ([Figure 2](#fig2){ref-type="fig"}M) and increased numbers of IFN-γ producing T cells ([Figure 2](#fig2){ref-type="fig"}N). This effect was not seen when cDC2s were sorted from Fcer1g^−/−^ mice ([Figures S3](#mmc1){ref-type="supplementary-material"}A and S3B). Transfer of convalescent PVM-IS did not enhance the capacity of cDC1s or MAR-1^-^ cDC2s to present viral antigen.

Immune complexes (ICs) were made from fluorescently labeled ovalbumin (OVA)-Alexa Fluor 647 mixed with two mouse OVA-specific IgG2c monoclonal antibodies (mAbs) and injected intratracheally at 6 dpi. Strikingly, 48 h later, all CD64 and MAR-1 staining had disappeared from the total pool of lung cDC2s as well as MCs when ICs were injected ([Figure 2](#fig2){ref-type="fig"}O). This was due to Fc receptor-mediated internalization by inf-cDC2s because the amount of internalized OVA-Alexa Fluor 647 in MHCII^+^CD11c^+^CD11b^+^ cells comprising cDC2s and MCs was much higher following injection of OVA-Alexa Fluor 647-IC compared with OVA-Alexa Fluor 647 alone ([Figure 2](#fig2){ref-type="fig"}P). Intracellular FcgR staining allowed us to discriminate the different DC subsets, and acquisition of CD64 and MAR-1 by inf-cDC2s licensed these cells to more efficiently internalize OVA-Alexa Fluor 647 (AF647)-ICs compared with OVA-AF647 alone ([Figures S3](#mmc1){ref-type="supplementary-material"}C and S3D). Thus, inf-cDC2s induced by respiratory virus infection acquire antigens via convalescent serum components and Fc receptors to primarily boost CD4^+^ Th cell immunity.

Inf-cDC2s Develop Normally in the Absence of IRF4 and IRF8 {#sec2.6}
----------------------------------------------------------

IRF8 drives cDC1 development, whereas IRF4 drives cDC2s. In line with the cDC2 origin of inf-DCs, IRF4 was expressed at baseline and minimally altered by infection ([Figures 3](#fig3){ref-type="fig"}A and 3B; [Figure S2](#mmc1){ref-type="supplementary-material"}F). Lung inf-cDC2s upregulated IRF8 relative to their MAR-1^−^ cDC2 counterparts, and this was even more marked after migration of inf-cDC2s to the MLN, where the intensity of IRF8 staining almost reached that of cDC1s ([Figure 3](#fig3){ref-type="fig"}A and 3B; [Figure S2](#mmc1){ref-type="supplementary-material"}G). We next questioned whether IRF8 was needed to drive inf-cDC2s development. *Irf8* ^*fl/fl*^ *Itgax-cre* mice lack cDC1, potentially affecting viral clearance and confounding comparisons with WT mice because of immunopathology. We therefore generated CD45.1 WT:CD45.2 *Irf8* ^*fl/fl*^ *Itgax-cre* mixed BM chimeric mice ([Figure 3](#fig3){ref-type="fig"}C) which were infected with PVM 12 weeks later. At 10 dpi, cDC1s in the lungs and MLNs were almost exclusively derived from the WT CD45.1 BM compartment ([Figure 3](#fig3){ref-type="fig"}D). In contrast, cDC2s and inf-cDC2s were derived equally well from the WT and *Irf*8^−/−^ BM compartments, although inf-cDC2s had a slightly higher WT:*Irf8* ^*fl/fl*^ *Itgax-cre* ratio compared with cDC2s ([Figure 3](#fig3){ref-type="fig"}D). Lack of IRF4 in CD11c^+^ cells of *Irf4* ^*fl/fl*^ *Itgax-cre* mice resulted in a reduction in cDC2s in the lungs and a severe reduction in migratory cDC2s in MLNs in the steady state ([@bib9]). Although lung inf-cDC2s were not affected by loss of IRF4 in infected mice, there was less migration of CCR7^+^ cDC2s and inf-cDC2s in *Irf4* ^fl/fl^ *Itgax*-cre mice to MLNs ([Figures S4](#mmc1){ref-type="supplementary-material"}A--S4E). A subset of CD301b(MGL2)^+^CD24^+^cDC2s known to induce Th2 cell responses ([@bib31], [@bib61]) was lower in the lungs and MLNs of *Irf4* ^*fl/fl*^ *Itgax*-*cre* mice; however, this was a minor population of all cDC2s ([Figure S4](#mmc1){ref-type="supplementary-material"}F).Figure 3IRF8 Controls the Gene Network in inf-cDC2s(A) Expression of IRF4 (top panel) and IRF8 (bottom panel) by different DC subsets in the lungs and MLNs 10 dpi with PVM.(B) Normalized Median Fluoresent Intensity (MFI) for IRF4 and IRF8 relative to the cDC2 subset, which is set to 0 for DC subsets in the lungs (top panel) or the different migratory cDC subsets in MLNs (bottom panel) 10 dpi with PVM. Error bars represent 95% confidence intervals. Data are representative of 3 independent experiments with 4--6 mice per group.(C) Schematic representation of CD45.1 WT:CD45.2 *Irf8*^*fl/fl*^*Itgax*-*cre* BM chimeras.(D) Normalized CD45.1/CD45.2 ratio relative to B cells of DC subsets in the lungs (left panel) and migratory cDCs in MLNs (right) 10 dpi with PVM. Data are representative of 2 independent experiments with 4--6 mice per group, analyzed with a one-way ANOVA with Sidak correction for multiple comparisons. Error bars indicate ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant.(E) UMAP plot of scRNA-seq data of pooled, sorted, live CD3-CD19-SiglecF-CD11c^+^MHCII^+^ cells from lungs of CD45.1 WT:CD45.2 *Irf8*^*fl/fl*^*Itgax*-*cre* chimeric mice 10 dpi with PVM, showing assigned clusters, and UMAPs showing expression of key annotation markers by color (gray, low expression; blue, high expression) (see also [Figures S5](#mmc1){ref-type="supplementary-material"}A--S5C).(F) UMAP plot overlay (left panel) similar to (E) but with the colors representing origin of the WT (teal) or *Irf8*^*fl/fl*^*Itgax*-cre (red) compartment and sample frequency per cluster (right panel).(G) Dot plot heatmap showing expression of selected (curated) and top DEG (data driven) per cluster. The dot size represents the percentage of cells expressing the gene, and the color represents the average expression of that gene within a cluster.(H) Heatmap showing relative expression of the top DEG retrieved from a microarray dataset of cDC2s and inf-cDC2s sorted from IAV-infected lungs 4 dpi, plotted on lung inf-cDC2s, migratory and non-migratory cDC1 and cDC2 clusters of an scRNA-seq dataset 10 dpi with PVM, and vice versa. Relative expression was calculated by transforming the normalized expression values to a 0-1 scale for each gene separately.(I) Histogram showing *Irf8* RNA expression profiles of different lung cDC clusters derived from the WT compartment of WT:*Irf8*^*fl/fl*^*Itgax*-*cre* chimeras 10 dpi with PVM (left panel), UMAP showing *Irf8* expression (center panel), and a UMAP plot showing *Irf8* regulon activity as predicted by SCENIC (right panel) on lung cells derived from the WT and *Irf8*^−/−^ compartments. Cells in which the *Irf8* regulon is active (i.e., regulon activity exceeds a regulon-specific area under the curve \[AUC\] threshold) are shown in blue.(J) Venn diagram detailing overlap between different cDC2 subsets of Irf8-dependent DEG reaching a log-fold change of ± 0.25.(K) Heatmap of normalized expression of Irf8-dependent genes in cDC2 subsets derived from lungs of CD45.1 WT:CD45.2 *Irf8*^*fl/fl*^*Itgax*-*cre* chimeric mice 10 dpi with PVM. Genes with a log fold-change lower than −0.25 (i.e., intrinsically induced by IRF8) are shown in bold blue, and genes with a log fold-change higher than 0.25 (i.e., intrinsically suppressed by IRF8) are shown in bold black. Group names are based on the cDC2 subsets in which the log fold threshold was reached (J).

Inf-cDC2s Express Genes Shared with All DC Subsets and MCs {#sec2.7}
----------------------------------------------------------

Single-cell RNA sequencing (scRNA-seq) analysis was performed on sorted lineage^−^CD11c^+^MHCII^+^ cells obtained from the lungs of WT:*Irf8* ^*fl/fl*^ *Itgax-cre* chimeric mice 10 dpi with PVM, according to expression of congenic markers. An unsupervised Uniform Manifold Approximation and Projection (UMAP) was performed on 9,446 WT CD45.1 and 9,142 *Irf8* ^*fl/fl*^ *Itgax-cre* CD45.2 cells derived from chimeric mice ([Figure 3](#fig3){ref-type="fig"}E). To account for non-IRF8-related differences because of the congenic background, the same analysis was performed on 10,362 WT CD45.1 and 10,142 non-transgenic CD45.2 cells sorted from the lungs of infected WT:*Irf8* ^*fl/fl*^ *Itgax-cre* ^*−*^ chimeric mice ([Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C). Cells were pooled into a single dataset, and their origin was visualized in a dual color-coded UMAP ([Figure 3](#fig3){ref-type="fig"}F; [Figure S5](#mmc1){ref-type="supplementary-material"}C).

Annotation of cell clusters was based on expression of curated and data-driven genes ([Figures 3](#fig3){ref-type="fig"}G and 3H). pDCs were defined as *Siglech* ^*+*^ *Tcf4* ^*+*^ *Ccr9* ^*+*^ *Bst2* ^*+*^ and cDCs as *Flt3* ^+^ *Dpp4* ^+^ *Zbtb46* ^+^. The cDCs were further subdivided into "non-migratory" (*Ccr7* ^lo^ *Nudt17* ^lo^) cDC1s (*Cd81* ^+^ *Gcsam* ^+^ *Xcr1* ^+^ *Irf8* ^+^) and cDC2s (*Sirpa* ^+^ *S100a4* ^+^ *CD209a* ^+^) and "migratory" (*Ccr7* ^hi^ *Nudt17* ^*hi*^ profile) cDC1s (*Cd81* ^+^ *Gcsam* ^+^ *Laptmb4* ^+^ *Ncoa7* ^+^; the latter two genes were chosen because of downregulation of *Xcr1* mRNA) and cDC2s (*S100a4* ^*+*^ *Anxa3* ^+^ *Cdc42ep3* ^+^). A small group of cDCs highly expressed genes associated with cell proliferation (*Mki67* ^+^ *Stmn1* ^+^), confirming reports that cDCs can proliferate in the lungs ([@bib17]). Approximately one-third of lung MHCII^+^CD11c^+^ cells at 10 dpi with PVM in chimeric mice were MCs (expression of *Mafb*, *Mertk*, and *Fcgr1* and lack of expression of *Flt3*, *Zbtb46*, and *Dpp4*; [Figures 3](#fig3){ref-type="fig"}E and 3F). In the cDC2 compartment, inf-cDC2s were identified based on expression of *Fcgr1* and other genes (e.g., *Irf8* and *Irf4*). Although, in flow cytometry analysis, up to 60% of all cDCs were inf-cDC2s ([Figures 1](#fig1){ref-type="fig"}C and 1G), scRNA-seq revealed only a representation of approximately 20% ([Figure 3](#fig3){ref-type="fig"}E). This most likely stems from differences in the kinetics of mRNA and protein expression of marker genes, and inf-cDC2s might be masked by downregulation or delayed expression of *Fcgr1* mRNA. The most likely cluster where inf-cDC2s are to be expected is the migratory cDC2 cluster because this cluster contains the highest number of *Irf8* mRNA^+^ cells.

To compare the differentially expressed genes (DEG) between cDC2s and inf-cDC2s defined by viral infection, we mapped the top DEG between sorted inf-cDC2s and cDC2s of lungs of IAV-infected mice onto cDC2 clusters of the scRNA-seq data of PVM-infected mice and vice versa ([Figure 3](#fig3){ref-type="fig"}H). The top DEG of the inf-cDC2s subset clearly overlapped between both models of viral respiratory infection ([Figure 3](#fig3){ref-type="fig"}H), illustrating a common signature of inf-cDC2s. Compared with non-migratory cDC2s and migratory cDC2s, the most discriminative genes in inf-cDC2s were related to a type I IFN signature (e.g., *Stat1, Iigp1, Rsad2, ifi205, Isg20, Ifit1,* and *Ifit3*), genes encoding for pro-inflammatory cytokines (e.g., *Ccl5*, *Cxcl9*, and *Cxcl10*), and genes promoting Th1 cell differentiation (e.g., *Il12b*), whereas genes involved in Th2 cell development appeared to be downregulated (e.g., *Irf4*, *Klf4*, and *Mgl2*) ([Figures 3](#fig3){ref-type="fig"}G, 3H, and 3K). In line with the flow cytometry data, cDC1s were exclusively derived from the WT compartment ([Figure 3](#fig3){ref-type="fig"}F). MCs and the entire cDC2 lineage, including inf-cDC2s, developed equally well from both compartments. Sorted pDCs were almost completely derived from the IRF8-deficient compartment. We reported earlier that IRF8-deficient pDCs have higher expression of CD11c, IRF4, and MHCII, which explains why IRF8-deficient pDCs are present in the pool of CD11c^+^MHCII^+^ cells of these WT:*Irf8* ^fl/fl^ *Itgax-cre* chimeras ([@bib93]). In WT:WT control mixed BM chimeras, all cell populations were equally derived from both compartments ([Figure S5](#mmc1){ref-type="supplementary-material"}).

IRF8 Drives Maturation in inf-cDC2s {#sec2.8}
-----------------------------------

The precise gene expression module depending on IRF8 in cDCs has been difficult to elucidate because cDC1s do not develop in the absence of IRF8 ([@bib73], [@bib93]). However, the finding that IRF8 was turned on in inf-cDC2 without affecting development gave us the unique opportunity to study the IRF8-dependent genes in cDC2s. We quantified IRF8 regulon activity in cells of chimeric mice by applying the single-cell regulatory network inference and clustering (SCENIC) workflow ([@bib1]), which predicted a high-confidence regulon governed by IRF8 in the cDC1 lineage. This IRF8 regulon activity was also observed during cDC2 maturation and migration upon PVM infection, supported by *Irf8* mRNA expression in cells with IRF8 regulon activity ([Figure 3](#fig3){ref-type="fig"}I). We then compared DEG between *Irf8* ^*−/−*^ and WT cells in each cluster of cDC2s (i.e., non-migratory cDC2s, migratory cDC2s, and inf-cDC2s). After removal of 9 genes that were differentially expressed because of the congenic background in chimeric mice, a small set of 88 genes was obtained ([Figures 3](#fig3){ref-type="fig"}J and 3K). Most of the IRF8-dependent genes were involved in co-stimulation, T cell differentiation (e.g., promotes *Il12b* and suppresses *Irf4*, *Klf4*, and *Ccrl2*), and antigen processing and presentation (e.g., *Siglecg*, *H2-DMb2*, *Cst3*, *Fcgrt*, and *Nlrc5*). In addition to *Irf8*, other transcription factors associated with cDC1 development and function were adopted by migratory cDC2s, like *Id2*, *Batf3*, *IL12b*, *Tap1*, *Tap2*, *Tapbp*, *Tapbpl*, *B2m*, *Psme* genes, *Swap70*, *Nfil*, *Nlrc5*, and *Rab43* ([@bib52], [@bib59]; [Figures 3](#fig3){ref-type="fig"}G and 3K). Genes typically associated with cDC2 function (*Irf4*, *Ciita*, *H2-DMb2*, and *Siglecg*) were upregulated in *Irf*8^−/−^ cells ([Figure 3](#fig3){ref-type="fig"}K).

Inf-cDC2s Are Induced in a Cell-Intrinsic, Type I IFN-Dependent Manner {#sec2.9}
----------------------------------------------------------------------

PVM and IAV are RNA viruses known to contain TLR3 and TLR7 agonists, whereas the fusion protein of PVM is a known TLR4 agonist. To study the signals leading to inf-cDC2 development, we set up Flt3L BM cultures ([@bib54]), which were exposed to agonists of TLR3 (poly(I:C)), TLR4 Lipopolysaccharide (LPS), TLR7 (R848), and TLR9 (CpG motifs). Because Ingenuity Pathway Analysis (IPA) of the transcriptional profile of inf-cDC2s suggested that Interferon alpha/beta receptor 1 (IFNAR1), STAT1, IRF7, and IRF8 were potential upstream regulators of the distinct gene expression profile ([Figure S2](#mmc1){ref-type="supplementary-material"}E), cells were also exposed to type 1 and type 2 IFN. After 9 days of culture, XCR1^+^CD172a^−^ cDC1s and XCR1^−^CD172a^+^ cDC2s were clearly distinguishable. Without addition of TLR ligands, some cDC2s already expressed MAR-1 and low amounts of CD64. Addition of LPS, poly(I:C), R848, and CpG motifs induced much higher MAR-1 and CD64 on cDC2s, and these cells now resembled inf-cDC2s. Upregulation of MAR-1 on cDC1s was also seen after exposure to poly(I:C) and imiquimod, although the shift was bigger in cDC2s. Type 1 IFN induced CD64 and MAR-1 on cDC2s and cDC1s, whereas IFN-γ induced CD64 and MAR-1 exclusively on cDC2s ([Figure 4](#fig4){ref-type="fig"} A).Figure 4MAR-1, CD64, and IRF8 Are Induced in a Type I IFN-Dependent Manner in cDC2s(A) On day 8, Flt3L bone marrow dendritic cells (BMDCs) were stimulated with LPS (200 ng/mL), poly(I:C) (1,000 ng/mL), R848 (10 ng/mL), CpG (100 ng/mL), IFNα (200 ng/mL), or IFNγ (200 ng/mL). cDCs were harvested 20 h later and analyzed for expression of MAR-1 and CD64.(B--D) Flt3L culture of a 50:50 mix of CD45.1 WT (*Ifnar1*^*+/+*^) and CD45.2 *Ifnar1*^*−/−*^ DCs that was unstimulated (B) or stimulated with R848 (C) or IFNα (D) and harvested 20 h later (see also [Figures S3](#mmc1){ref-type="supplementary-material"}E and S3F).(E--G) Uptake of OVA-AF647 (10 μg/mL) added alone or as OVA-AF647-IgG2c-IC to Flt3L culture of a 50:50 mix of CD45.1 WT and CD45.2 *Ifnar1*^*−/−*^ (E) or *Fcer1g*^*−/−*^ (F) type 2 cDCs and surface expression (MFI) of MAR-1 and CD64 (G) on Flt3L (un)stimulated WT and *Ifnar1*^*−/−*^ BM-derived type 2 cDCs 20 h after addition of OVA-AF647 (10 μg/mL) alone or as OVA-AF647-IgG2c-IC. Data are representative of 3 independent experiments with 3 mice per group, analyzed with a two-way ANOVA with Sidak correction for multiple comparisons. Error bars indicate ± SEM. ^∗∗^p \< 0.01 (see also [Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H).(H and I) Flow cytometry plots pre-gated on live CD3^−^CD19^−^CD172a^+^ DCs in the lungs (H) and migratory DCs in MLNs (I) of WT (*Ifnar1*^*+/+*^) and *Ifnar1*^*−/−*^ mice 10 dpi with PVM. Histograms show expression of MAR-1 on the different DC subsets (see also [Figures S2](#mmc1){ref-type="supplementary-material"}H--S2J).(J and K) Expression of IRF4 and IRF8 shown as MFI by DC subsets in the lungs (J) and MLNs (K) of WT (*Ifnar1*^*+/+*^) and *Ifnar1*^*−/−*^ mice 4 dpi with IAV. Data are representative of 2 independent experiments with 4--5 mice per group and were analyzed with a two-way ANOVA with Sidak correction for multiple comparisons. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant.(L) Schematic representation of CD45.1 WT:CD45.2 *Ifnar1*^*−/−*^ BM chimeras.(M) Flowcytometry plots pre-gated on WT (*Ifnar1*^*+/+*^) or *Ifnar1*^*−/−*^−derived live CD3^−^CD19^−^ migratory CD172a^+^ DCs in MLNs of CD45.1 WT:CD45.2 *Ifnar1*^*−/−*^ chimeric mice 10 dpi with PVM.(N) Normalized CD45.1/CD45.2 ratio relative to B cells of migratory cDCs in the MLN 10 dpi with PVM. Data are representative of 2 independent experiments with 5--7 mice per group, analyzed with a one-way ANOVA with Sidak correction for multiple comparisons. Error bars indicate ± SEM. ^∗∗^p \< 0.01.(O) Expression of MHCII and CD86 shown as MFI by DC subsets in the lungs of CD45.1 WT:CD45.2 *Ifnar1*^*−/−*^ chimeric mice 10 dpi with PVM. Data are representative of 2 independent experiment with 5--7 mice per group and were analyzed with a two-way ANOVA with Sidak correction for multiple comparisons. ^∗∗^p \< 0.01; ns, not statistically significant.

Mixed cultures set up from 50% CD45.1 WT and 50% CD45.2 *Ifnar1* ^−/−^ BM cells stimulated by medium or TLR7 ligation revealed that spontaneous upregulation of MAR-1 on cDC2s was only seen in the WT compartment but not in the *Ifnar1* ^−/−^ compartment of these mixed cultures, suggesting autocrine production of type 1 IFN and cell-intrinsic IFNAR1 signaling ([Figure 4](#fig4){ref-type="fig"}B). Likewise, TLR7-induced upregulation of MAR-1 and CD64 on the WT fraction of cells was almost completely absent in the *Ifnar1* ^−/−^ fraction, suggesting a role of autocrine type 1 IFN in upregulation of activating Fc receptors on cDCs driven by TLR ligation ([Figure 4](#fig4){ref-type="fig"}C). Similar results were found for the other TLR ligands (data not shown). Type 1 IFN induced upregulation of CD64 and MAR-1 in the WT fraction but not in the *Ifnar1* ^−/−^ fraction.

Upregulation of activating Fc receptors *in vitro* increased the capacity of cDC1s and cDC2s to take up OVA-AF647-ICs compared with OVA-AF647 alone ([Figures 4](#fig4){ref-type="fig"}E and 4F; [Figures S3](#mmc1){ref-type="supplementary-material"}G and S3H). This increased uptake was intrinsically dependent on type I IFN signaling and expression of the Fc common gamma chain ([Figures 4](#fig4){ref-type="fig"}E and 4F). Moreover, the uptake of OVA-AF647-ICs was accompanied by loss of surface expression of MAR-1 and CD64 because of internalization ([Figure 4](#fig4){ref-type="fig"}G).

To validate these findings *in vivo*, *Ifnar1* ^−/−^ and WT mice were infected with PVM and analyzed for DC subsets at 10 dpi. In the absence of type I IFN signaling, inf-cDC2s were hardly detectable in the lungs, whereas MAR-1^+^ MCs were intact ([Figure 4](#fig4){ref-type="fig"}H). This was mostly seen in MLNs, in which migratory inf-cDC2s were completely lacking ([Figure 4](#fig4){ref-type="fig"}I). Similar findings were seen in IAV-infected mice at 4 dpi ([Figures S2](#mmc1){ref-type="supplementary-material"}H and S2I). Moreover, we found that IRF8 expression was reduced in lung and MLN cDC2s and MCs but not in cDC1s of virus-infected *Ifnar1* ^−/−^ mice compared with WT controls ([Figures 4](#fig4){ref-type="fig"}J and 4K), indicating that type 1 IFN signaling acts as an upstream inducer of IRF8 selectively in cDC2s and MCs. No changes were observed in IRF4 expression in virus-infected WT and *Ifnar1* ^−/−^ mice ([Figures 4](#fig4){ref-type="fig"}J and 4K).

In mixed WT:*Ifnar1* ^−/−^ BM chimeras ([Figure 4](#fig4){ref-type="fig"}L) infected with PVM, induction of inf-cDC2s also intrinsically relied on IFNAR1 signaling *in vivo*. In MLNs at 10 dpi, inf-cDC2s were almost exclusively derived from the WT component of chimeric mice ([Figures 4](#fig4){ref-type="fig"}M and 4N), whereas cDC1s were equally derived from WT and *Ifnar1* ^−/−^ cells. The increased maturation state of lung inf-cDC2s, reflected by enhanced expression of co-stimulatory molecules compared with cDC2s, was also intrinsically dependent on IFNAR1 signaling ([Figure 4](#fig4){ref-type="fig"}O).

Taken together, these data show that TLR-driven activation of type I IFN production causes cell-intrinsic IFNAR1 signaling, inducing activation of migratory cDC2s that acquire the phenotype of inf-cDC2s in virally infected mice.

Inf-cDC2s Are Found Abundantly in Other Models of Inflammation and Infection {#sec2.10}
----------------------------------------------------------------------------

We reported previously, using a Th2 cell-driven house dust mite (HDM) mouse model of asthma, that MAR-1^+^ CD64^+^ MHCII^+^ CD11c^+^ cells present Der p 1 antigens to *ex vivo* allergen-specific T cells and prime for asthma upon adoptive transfer to naive mice. However, because MAR-1 and CD64 were considered markers of monocyte-derived macrophages at that time, and based on the dependency on CCR2, we called these cells inflammatory monocyte-derived DCs ([@bib45], [@bib82]). Given the phenotype of inf-cDC2s in viral lung infections, we repeated this experiment with intratracheal (i.t.) administration of 100 μg of HDM. As reported, MAR-1^+^ CD64^int^ CD172a^+^ DCs were found to accumulate in MLNs 3 days after HDM administration in WT mice but not *Ifnar1* ^*−/−*^ mice ([Figure 5](#fig5){ref-type="fig"} A). These MAR-1^+^ DCs expressed the same amount of the common cDC marker CD26 as cDC1s and MAR-1^−^ cDC2s, arguing for their pre-cDC origin ([Figure 5](#fig5){ref-type="fig"}B). Like in viral infection, the total cDC2 population in MLNs acquired intermediate IRF8 expression ([Figure 5](#fig5){ref-type="fig"}C) upon HDM administration, but this was not seen in *Ifnar1* ^−/−^ mice. Selected pro-Th2 cell cytokines known to affect DCs, like Thymic stromal lymphopoietin (TSLP) and IL-33, were unable to induce inf-cDC2s *in vitro* ([Figure S3](#mmc1){ref-type="supplementary-material"}F). HDM sensitization in combination with LPS and beta-glucans promotes neutrophilic inflammation ([@bib43]), and mixed Th2-Th17 cell pulmonary immunity is also found in severe asthmatics. Inf-cDC2s were capable of priming naive Der p 1-specific (1-Der) T cells and induce RORγt and IL-17A expression, but less efficiently than CD64^−^ cDC2s ([Figures 5](#fig5){ref-type="fig"}D--5F). Sorted lung MCs were again unable to present endogenously acquired antigen to 1-Der T cells *ex vivo*, but when preprocessed exogenous Der p 1 peptide was added, they readily induced proliferation.Figure 5Inf-cDC2s Are Found in Other Models of Inflammation and Infection(A) Flowcytometry plots pre-gated on live CD3^−^CD19^−^ migratory CD172a^+^ DCs in MLNs of WT (*Ifnar1*^*+/+*^) and *Ifna1r*^*−/−*^ mice 3 days after 100 μg HDM administration i.t.(B) CD26 expression by the different DC subsets in MLNs of WT mice 3 days after 100 μg HDM administration i.t.(C) Expression of IRF8, shown as MFI, by the total cDC2 subset in MLNs of WT (*Ifnar1*^*+/+*^) and *Ifnar1*^*−/−*^ 3 days after 100 μg HDM administration i.t. The experiment had 4--6 mice per group and was analyzed with a one-way ANOVA with Sidak correction for multiple comparisons. ^∗^p \< 0.05; ns, not statistically significant.(D) Proliferation profile of CTV-labeled Der p 1-specific CD4^+^ TCR transgenic T cells cocultured for 4 days with the different DC subsets sorted from MLNs (top row) or lungs (bottom row) 72 h after i.t. challenge with HDMs (75 μg) in combination with LPS (300 ng) and beta-glucans (30 μg). For the peptide control, 1 μg/mL of Der p 1 peptide was added *ex vivo*.(E and F) Absolute number total divided (E) and RORγt^+^, IL-17^+^, and GATA3^+^ (F) Der p 1-specific TCR transgenic CD4^+^ T cells and IL-4 measured in supernatants of coculture as in (D). One-way ANOVA with Sidak correction for multiple comparisons. Error bars indicate ± SEM. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant.(G) Gating strategy of DC subsets in ELNs 48 h after i.d. injection of the ear pinna with mock, nonviable Ms or Nb L3 larvae; pre-gated on live CD3^−^B220^−^Ly6G^−^Ly6C^−^ cells.(H and I) Expression of IRF8 by different DC subsets in ELNs 48 h after i.d. immunization of the ear pinna with Ms or Nb or mock immunization, shown in representative histograms (H) and as MFI (I). Data are representative of 2 independent experiment with 5 mice per group and were analyzed with a one-way ANOVA with Sidak correction for multiple comparisons. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant.(J) Proportion of CTFR-Ms^+^/Nb^+^ and/or photoconverted DC subsets in ELNs 48 h after i.d. immunization and violet laser exposure of the ear pinna. Data are representative of 2 independent experiments with 4 Kaede mice per group and were analyzed with a one-way ANOVA with Sidak correction for multiple comparisons. ^∗^p \< 0.05, ^∗∗^p \< 0.01; ns, not statistically significant.

To study whether inf-cDC2s were also found in other tissues, we examined the distinct DC populations isolated from mouse ear draining LNs (ELNs) 48 h after intradermal (i.d.) injection in the ear pinna of nonviable freeze-thawed *Nippostrongylus brasiliensis* L3 larvae (Nb) or heat-killed *Mycobacterium smegmatis* (Ms) as models for skin type 2 parasitic and type 1 mycobacterial infection, respectively ([@bib23]). An increase in MHCII^hi^ DCs in ELNs was seen 48 h after Ms and Nb infection, mainly caused by influx of skin CD11b^+^ and triple-negative (CD11b^−^CD103^−^CD326^−^) CD26^+^ XCR1^−^ cDC2s ([Figure 5](#fig5){ref-type="fig"}G and data not shown). Again, no CD26^lo^CD64^hi^ MCs could be identified in the actively migrating MHCII^hi^ DC population in draining LNs ([Figure 5](#fig5){ref-type="fig"}G). Unique to the skin, a CD26^lo^MHCII^hi^ population in ELNs was identified as Langerhans cells (LCs) expressing CD11b and CD326 but not CD64. Conventional CD26^+^ DCs were further subdivided in XCR1^+^ cDC1s, CD11b^+^ cDC2s, and TN cDCs. CD11b^+^ cDC2s acquired expression of CD64 and MAR-1 ([Figure 5](#fig5){ref-type="fig"}H) upon immunization, the degree of which correlated with intracellular IRF8 expression ([Figure 5](#fig5){ref-type="fig"}I). In CD64^+^MAR-1^+^ skin inf-cDC2s in the Ms and Nb model, the intensity of IRF8 was at least as high as in cDC1s, potentially because a subset of CD326^+^ skin cDC1s express lower IRF8 compared with other tissue cDC1s ([Figure 5](#fig5){ref-type="fig"}I; [@bib100]).

To evaluate active migration to ELNs, we immunized Kaede mice, which ubiquitously express a violet light-sensitive photoconvertible fluorescence protein, with CellTrace™ Far Red (CTFR)-labeled Nb and Ms and studied migration at 48 h ([@bib99]; [Figure 5](#fig5){ref-type="fig"}J). In keeping with a previous report ([@bib22]), CD11b^+^ cDC2s accounted for the majority of Ms and Nb antigen transported to the ELN. Photoconverted skin DCs were found exclusively in the MHCII^hi^ fraction of ELNs. MAR-1^+^ and/or CD64^+^ cDC2s of the skin were a *bona fide* migratory DC population.

Thus, inf-cDC2s that express IRF8 and develop in an IFNAR1-dependent manner can be found in multiple models of infection and inflammation in and outside of the lung.

Discussion {#sec3}
==========

Here we have shown that what are known as "monocyte-derived inflammatory DCs" are a mixture of monocyte-derived MCs that have little migratory and APC potential and *bona fide* pre-cDC-derived, CD26-expressing inf-cDC2s that depend on Flt3L but not on GM-CSF. Inf-cDC2s had upregulated expression of cytokines, chemokines, costimulatory molecules, and Fc receptors in an IFNAR1-dependent manner. Given these hybrid features of inf-cDC2s, sharing expression of activating Fc receptors with MCs and macrophages and the potential to upregulate IRF8 like cDC1s, we suspect that they have often contaminated other populations of APCs. Because most investigators have not used CD26 to precisely define cDCs in the CD11b^+^CD11c^+^MHCII^+^ pool of cells, the mistaken identity of contaminating inf-cDC2 cells might be the main reason why *in vivo* monocyte-derived DCs have been shown to be excellent APCs with migratory capacity in models of allergy, vaccination, infection, and cancer ([@bib21], [@bib58], [@bib64], [@bib72], [@bib76], [@bib82], [@bib97]). When we carefully excluded inf-cDC2s from monocyte-derived "DCs," the latter were no longer able to process and present native antigens to naive CD4^+^ and CD8^+^ T cells.

The argument that moDCs are important for immunopathology and Th1 cell-mediated immunity has also heavily relied on use of *Ccr2* ^−/−^ mice, which have defects in monocyte egress from the BM, moDC and MC recruitment, and Th1 cell induction ([@bib50], [@bib55], [@bib70], [@bib76], [@bib92], [@bib95]). Our data now show that inf-cDC2s are IL-12-producing mature APCs that resemble moDCs and also depend on CCR2 for migrating to the lungs, at least in the setting of respiratory viral infection. These data are in line with reports describing CCR2 expression on circulating Ly6C^hi^SiglecH^+^ pre-cDC2s and dependence of CD11b^+^ cDC2s on CCR2 in mucosal tissues such as the gut and lungs ([@bib79], [@bib87], [@bib89]). Use of the CCR2 model and the presence of CD64^+^MAR-1^+^-expressing DCs in MLNs have also misled us to suggest that moDCs were drivers of Th2 cell immunity in the HDM model of allergy ([@bib82]), an interpretation we would now like to revise. By using CD26 as a defining marker, it is very clear that the moDCs we proposed to migrate to LNs to induce Th2 cell priming after high-dose HDM exposure were, in fact, inf-cDC2s ([@bib82]), and we additionally demonstrate how these emerge in a type 1 IFN-dependent manner. These findings also realign our work with that of others proposing that lung inflammatory Ly6C^+^ moDCs are more related to macrophages and have a poor capacity to migrate to lung LNs or prime T cell responses ([@bib71], [@bib77], [@bib109]).

It has been proposed that CD209 (DC-SIGN) is a unique marker for moDCs that identifies DCs with the highest degree of maturity and potential to cross-present antigens ([@bib21], [@bib70]). When carefully separating MCs from inf-cDC2s, in our hands, CD209 mRNA was only found on cDC2s. Cell surface CD88 and CX3CR1 are potentially much better and stable positive discriminators of MCs, particularly in combination with CD26 to identify cDCs ([@bib78]). We no longer recommend exclusive use of CD64 or MAR-1 to separate cDCs from MCs ([@bib17], [@bib40], [@bib41], [@bib82], [@bib95]).

Mutant *Irf8* (BHX2), *Irf8* ^*fl/fl*^ *Itgax-cre*, and *Irf8* ^*fl/fl*^ *Zbtb46-cre* mice have been used or proposed as models to interrogate the *in vivo* functions of cDC1s, whereas *Irf4* ^*fl/fl*^ *Itgax-cre* mice have been used to probe cDC2 function ([@bib2], [@bib8], [@bib9], [@bib11], [@bib60], [@bib81], [@bib86]). Because IRF8 is induced in inf-cDC2s and regulates a functional module, including antigen-presentation capacity, chemokine production, and cytokine production, we caution to draw the conclusion that a particular phenotype of *Irf8* mutant mice would be exclusively due to defects of cDC1s. It will be very important to better understand how IRF8 expression is regulated in cDC2s and whether this is different compared with cDC1s.

Our work has implications for understanding (cross)-presentation and uptake of opsonized antigens through use of convalescent serum. In the steady state, cDC1s have a higher capacity to cross-present cell-bound and particulate antigens to CD8^+^ T cells, and cDC2s are better at inducing CD4^+^ T cell responses ([@bib16], [@bib27], [@bib47]). However, many studies have shown that CD11b^+^ DCs and moDCs (MCs) can also stimulate CD8 immunity, particularly *in vitro* and after cytokine activation *in vivo* ([@bib15], [@bib21], [@bib26], [@bib62]). As an example, we and others have shown that cDC1s prime CD8^+^ T cell immunity to influenza virus infection ([@bib33], [@bib46]), whereas others have claimed that CD11b^+^ cDC2s are more proficient ([@bib2], [@bib10]). Here, using PVM-specific TCR transgenic mice, we show that cDC1s and *bona fide* CD11b^+^ inf-cDC2s from virus-infected mice are almost equally potent in stimulating CD8^+^ T cells *ex vivo* and that inf-cDC2s simultaneously stimulate CD4^+^ T cell responses, inducing polarization of IFN-γ-producing cells. Contrary to dogma, MCs were unable to present viral antigens to naive CD8^+^ or CD4^+^ T cells. Therefore, the role of tissue-residing MCs might rather be found in orchestration of the peripheral effector response or inflammation in the presence of antibody-complexed antigen. It will be important to examine whether convalescent serum can activate MCs to produce pro-inflammatory cytokines and chemokines. This is a pertinent question for patients with severe viral infections causing acute lung injury and ARDS (such as COVID-19 and influenza). It has been proposed that convalescent serum be given during the acute lung injury phase, but if this leads to activation of Fc receptor-bearing MCs, it could be detrimental ([@bib19]).

Triggering of activating Fc receptors by opsonized antigens or ICs can lead to enhanced APC function of moDCs ([@bib83]), whereas inhibitory Fc receptors (FcRIIb) suppress APC function ([@bib53]). However, most studies that interrogated expression of Fc receptors on steady-state cDCs *in vivo* only demonstrated inhibitory Fc receptors on cDCs and pDCs and extremely low expression of activating FcγRI (CD64), FcγRIII, or FcγRIV receptors (summarized in [@bib40], [@bib63], [@bib95]). Here we show that *bona fide* inf-cDC2s upregulate activating Fc receptors in a TLR- and type I IFN-dependent manner and proficiently use these activating receptors for enhanced presentation of opsonized viral antigens to CD4^+^ T cells upon transfer of convalescent serum, whereas CD8^+^ T cell responses are not altered. Fc receptor-mediated uptake can divert antigens to a more acidic endosomal compartment conducive to MHCII antigen processing. Mouse IgG2c-antigen IC injection *in vivo* led to rapid Fc receptor-mediated internalization of antigen in inf-cDC2s. More mechanistic studies are needed, but this ligand-induced internalization could be one of the main reasons why these cells have been ignored as major players in the uptake of ICs *in vivo*, a function that has traditionally been attributed to cDC1 in the steady state but could be an induced function on inf-cDC2s ([@bib42]).

In conclusion, in respiratory viral infection and allergy, inf-cDC2s are generated in a type I IFN-dependent manner to optimally prime CD4^+^ and CD8^+^ T cell immunity. It will be essential to revisit the role of APCs in various inflammation models because the function of inf-cDC2s may have been wrongly attributed to cDC1s or MCs.
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REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-mouse FceR1 alpha Monoclonal antibody (Armenian hamster, clone MAR-1), Biotin conjugatedThermo Fisher ScientificCat\#13-5898-85; RRID:[AB_466784](nif-antibody:AB_466784){#intref0010}Anti-mouse CD3e Monoclonal antibody (Armenian hamster, clone 145-2C11), PE-Cy5 conjugatedThermo Fisher ScientificCat\#15-0031-82; RRID:[AB_468690](nif-antibody:AB_468690){#intref0015}Anti-mouse CD3e Monoclonal antibody (Armenian hamster, clone 145-2C11), BUV737 conjugatedBD BiosciencesCat\#564618; RRID:[AB_2738868](nif-antibody:AB_2738868){#intref0020}Anti-mouse CD3e Monoclonal antibody (Armenian hamster, clone 145-2C11), Biotin conjugatedThermo Fisher ScientificCat\#13-0031-85; RRID:[AB_466320](nif-antibody:AB_466320){#intref0025}Anti-mouse CD3 Monoclonal antibody (Rat, clone 17A2), AF700 conjugatedThermo Fisher ScientificCat\#56-0032-82; RRID:[AB_529507](nif-antibody:AB_529507){#intref0030}Anti-mouse CD19 Monoclonal antibody (Rat, clone eBio1D3(1D3)), PE-Cy5 conjugatedThermo Fisher ScientificCat\#15-0193-83; RRID:[AB_657673](nif-antibody:AB_657673){#intref0035}Anti-mouse CD19 Monoclonal antibody (Rat, clone eBio1D3(1D3)), AF700 conjugatedThermo Fisher ScientificCat\#56-0193-82; RRID:[AB_837083](nif-antibody:AB_837083){#intref0040}Anti-mouse CD19 Monoclonal antibody (Rat, clone eBio1D3(1D3)), Biotin conjugatedThermo Fisher ScientificCat\#13-0193-85; RRID:[AB_657658](nif-antibody:AB_657658){#intref0045}Anti-mouse Ly-6G Monoclonal antibody (Rat, clone 1A8), BUV395 conjugatedBD BiosciencesCat\#563978; RRID:[AB_2716852](nif-antibody:AB_2716852){#intref0050}Anti-mouse Ly-6G Monoclonal antibody (Rat, clone 1A8), Biotin conjugatedBioLegendCat\#127604; RRID:[AB_1186108](nif-antibody:AB_1186108){#intref0055}Anti-mouse Ly-6C Monoclonal antibody (Rat, clone AL-21), AF700 conjugatedBD BiosciencesCat\#561237; RRID:[AB_10612017](nif-antibody:AB_10612017){#intref0060}Anti-mouse Ly-6C Monoclonal antibody (Rat, clone HK1.4), AF647 conjugatedBioLegendCat\#128010; RRID:[AB_1236550](nif-antibody:AB_1236550){#intref0065}Anti-mouse CD326 Monoclonal antibody (Rat, clone G8.8), BV711 conjugatedBioLegendCat\#118233; RRID:[AB_2632775](nif-antibody:AB_2632775){#intref0070}Anti-mouse CD11c Monoclonal antibody (Armenian hamster, clone N418), PE-Cy7 conjugatedThermo Fisher ScientificCat\#25-0114-82; RRID:[AB_469590](nif-antibody:AB_469590){#intref0075}Anti-mouse CD11c Monoclonal antibody (Armenian hamster, clone N418), eFluor 450 conjugatedThermo Fisher ScientificCat\#48-0114-82; RRID:[AB_1548654](nif-antibody:AB_1548654){#intref0080}Anti-mouse CD11c Monoclonal antibody (Armenian hamster, clone HL3), BV786 conjugatedBD BiosciencesCat\#563735; RRID:[AB_2738394](nif-antibody:AB_2738394){#intref0085}Anti-mouse I-A/I-E (MHCII) Monoclonal antibody (Rat, clone M5/114.15.2), APC-eFluor 780 conjugatedThermo Fisher ScientificCat\#47-5321-82; RRID:[AB_1548783](nif-antibody:AB_1548783){#intref0090}Anti-mouse I-A/I-E (MHCII) Monoclonal antibody (Rat, clone M5/114.15.2), FITC conjugatedThermo Fisher ScientificCat\#11-5321-85; RRID:[AB_465233](nif-antibody:AB_465233){#intref0095}Anti-mouse I-A/I-E (MHCII) Monoclonal antibody (Rat, clone M5/114.15.2), FITC conjugatedThermo Fisher ScientificCat\#56-5321-82; RRID:[AB_494009](nif-antibody:AB_494009){#intref0100}Anti-mouse CD103 Monoclonal antibody (Armenian hamster, clone 2E7), PE conjugatedThermo Fisher ScientificCat\#12-1031-83; RRID:[AB_465800](nif-antibody:AB_465800){#intref0105}Anti-mouse CD103 Monoclonal antibody (Armenian hamster, clone 2E7), Pacific Blue conjugatedBioLegendCat\#121418; RRID:[AB_2128619](nif-antibody:AB_2128619){#intref0110}Anti-mouse CD11b Monoclonal antibody (Rat, clone M1/70), BV605 conjugatedBD BiosciencesCat\#563015; RRID:[AB_2737951](nif-antibody:AB_2737951){#intref0115}Anti-mouse CD11b Monoclonal antibody (Rat, clone M1/70), V450 conjugatedBD BiosciencesCat\#560455; RRID:[AB_1645266](nif-antibody:AB_1645266){#intref0120}Anti-mouse CD11b Monoclonal antibody (Rat, clone M1/70), BUV737 conjugatedBD BiosciencesCat\#564443; RRID:[AB_2738811](nif-antibody:AB_2738811){#intref0125}Anti-mouse CD64 Monoclonal antibody (Mouse, clone X54-5/7.1), AF647 conjugatedBD BiosciencesCat\#558539; RRID:[AB_647120](nif-antibody:AB_647120){#intref0130}Anti-mouse CD64 Monoclonal antibody (Mouse, clone X54-5/7.1), PE conjugatedBD BiosciencesCat\#558455; RRID:[AB_647241](nif-antibody:AB_647241){#intref0135}Anti-mouse CD64 Monoclonal antibody (Mouse, clone X54-5/7.1), BV711 conjugatedBioLegendCat\#139311; RRID:[AB_2563846](nif-antibody:AB_2563846){#intref0140}Anti-mouse CD64 Monoclonal antibody (Mouse, clone X54-5/7.1), PE-Cy7 conjugatedBioLegendCat\#139313; RRID:[AB_2563903](nif-antibody:AB_2563903){#intref0145}Anti-mouse CD24 Monoclonal antibody (Rat, clone M1/69), PE conjugatedThermo Fisher ScientificCat\#48-0242-82; RRID:[AB_1311169](nif-antibody:AB_1311169){#intref0150}Anti-mouse XCR1 Monoclonal antibody (Mouse, clone ZET), BV660 conjugatedBioLegendCat\#148220; RRID:[AB_2566410](nif-antibody:AB_2566410){#intref0155}Anti-mouse XCR1 Monoclonal antibody (Mouse, clone ZET), PE conjugatedBioLegendCat\#148204; RRID:[AB_2563843](nif-antibody:AB_2563843){#intref0160}Anti-mouse CD172a Monoclonal antibody (Rat, clone P84), PerCP-eFluor 710 conjugatedThermo Fisher ScientificCat\#46-1721-82; RRID:[AB_10804639](nif-antibody:AB_10804639){#intref0165}Anti-mouse CD172a Monoclonal antibody (Rat, clone P84), PE-Cy7 conjugatedBioLegendCat\#144008; RRID:[AB_2563546](nif-antibody:AB_2563546){#intref0170}Anti-mouse CD172a Monoclonal antibody (Rat, clone P84), APC conjugatedBD BiosciencesCat\#560106; RRID:[AB_1645218](nif-antibody:AB_1645218){#intref0175}Anti-mouse CD26 Monoclonal antibody (Rat, clone H194-112), FITC conjugatedBD BiosciencesCat\#559652; RRID:[AB_397295](nif-antibody:AB_397295){#intref0180}Anti-mouse CD26 Monoclonal antibody (Rat, clone H194-112), APC conjugatedBioLegendCat\#137807; RRID:[AB_10663403](nif-antibody:AB_10663403){#intref0185}Anti-mouse MerTK Monoclonal antibody (Rat, clone 2B10C42), APC conjugatedBioLegendCat\#151508; RRID:[AB_2650739](nif-antibody:AB_2650739){#intref0190}Anti-mouse Siglec-F Monoclonal antibody (Rat, clone E50-2440), PE conjugatedBD BiosciencesCat\#552126; RRID:[AB_394341](nif-antibody:AB_394341){#intref0195}Anti-mouse Siglec-F Monoclonal antibody (Rat, clone E50-2440), BV786 conjugatedBD BiosciencesCat\#740956; RRID:[AB_2740581](nif-antibody:AB_2740581){#intref0200}Anti-mouse CCR2 Monoclonal antibody (Rat, clone SA203G11), BV421 conjugatedBioLegendCat\#150605; RRID:[AB_2571913](nif-antibody:AB_2571913){#intref0205}Anti-mouse CCR2 Monoclonal antibody (Rat, clone 475301), PE conjugatedR&D SystemsCat\#FAB5538P; RRID:[AB_10718414](nif-antibody:AB_10718414){#intref0210}Anti-mouse CD45.1 Monoclonal antibody (Mouse, clone A20), BV605 conjugatedBioLegendCat\#110738; RRID:[AB_2562565](nif-antibody:AB_2562565){#intref0215}Anti-mouse CD45.2 Monoclonal antibody (Mouse, clone 104), AF700 conjugatedThermo Fisher ScientificCat\#56-0454-82; RRID:[AB_657752](nif-antibody:AB_657752){#intref0220}Anti-mouse CD45.2 Monoclonal antibody (Mouse, clone 104), PerCP-Cy5.5 conjugatedBD BiosciencesCat\#552950; RRID:[AB_394528](nif-antibody:AB_394528){#intref0225}Anti-mouse CD80 Monoclonal antibody (Rat, clone 16-10A1), PerCP-Cy5.5 conjugatedBD BiosciencesCat\# 560526, RRID:[AB_1727514](nif-antibody:AB_1727514){#intref0230}Anti-mouse CD86 Monoclonal antibody (Rat, clone PO3), PE-Cy7 conjugatedBioLegendCat\#105116; RRID:[AB_493600](nif-antibody:AB_493600){#intref0235}Anti-mouse CD88 Monoclonal antibody (Rat, clone 20/70), PE conjugatedBioLegendCat\#135806; RRID:[AB_2243735](nif-antibody:AB_2243735){#intref0240}Anti-mouse CD88 Monoclonal antibody (Rat, clone 20/70), PerCP-Cy5.5 conjugatedBioLegendCat\#135813; RRID:[AB_2750209](nif-antibody:AB_2750209){#intref0245}Anti-mouse CD197 (CCR7) Monoclonal antibody (Rat, clone 4B12), PE-Cy7 conjugatedThermo Fisher ScientificCat\#25-1971-82; RRID:[AB_469652](nif-antibody:AB_469652){#intref0250}Anti-mouse B220 Monoclonal antibody (Rat, clone RA3-6B2), BUV395 conjugatedBD BiosciencesCat\#563793; RRID:[AB_2738427](nif-antibody:AB_2738427){#intref0255}Anti-mouse IRF4 Polyclonal antibody (Goat, clone M-17), unconjugatedSanta Cruz BiotechnologyCat\#sc-6059; RRID:[AB_2127145](nif-antibody:AB_2127145){#intref0260}Anti-mouse IRF8 Monoclonal antibody (Rat, clone V3GYWCH), PerCP-eFluor 710 conjugatedThermo Fisher ScientificCat\#46-9852-82; RRID:[AB_2573904](nif-antibody:AB_2573904){#intref0265}Anti-mouse IRF8 Monoclonal antibody (Rat, clone V3GYWCH), APC conjugatedThermo Fisher ScientificCat\#17-9852-82; RRID:[AB_2573318](nif-antibody:AB_2573318){#intref0270}Anti-goat Polyclonal antibody (Donkey), AF647 conjugatedThermo Fisher ScientificCat\#A-21447; RRID:[AB_2535864](nif-antibody:AB_2535864){#intref0275}Anti-mouse IL-12 Monoclonal antibody (Rat, clone C15.6), APC conjugatedBD BiosciencesCat\#554479; RRID:[AB_395420](nif-antibody:AB_395420){#intref0280}Anti-mouse CD3e Monoclonal antibody (Armenian hamster, clone 145-2C11), APC-Cy7 conjugatedBD BiosciencesCat\#557596; RRID:[AB_396759](nif-antibody:AB_396759){#intref0285}Anti-mouse CD4 Monoclonal antibody (Rat, clone RM4-5), BV605 conjugatedBD BiosciencesCat\#563151; RRID:[AB_2687549](nif-antibody:AB_2687549){#intref0290}Anti-mouse CD8 Monoclonal antibody (Rat, clone 53-6.7), PerCP-Cy5.5 conjugatedThermo Fisher ScientificCat\#45-0081-82; RRID:[AB_1107004](nif-antibody:AB_1107004){#intref0295}Anti-mouse CD44 Monoclonal antibody (Rat, clone IM7), redFluor 710 conjugatedTonbo BiosciencesCat\#80-0441; RRID:[AB_2621985](nif-antibody:AB_2621985){#intref0300}Anti-mouse IFN-g Monoclonal antibody (Rat, clone XMG1.2), PE-eFluor 610 conjugatedThermo Fisher ScientificCat\#61-7311-82; RRID:[AB_2574662](nif-antibody:AB_2574662){#intref0305}Anti-mouse CD209a Monoclonal antibody (Mouse, clone MMD3), eFluor 660 conjugatedThermo Fisher ScientificCat\#50-2094-82; RRID:[AB_11219065](nif-antibody:AB_11219065){#intref0310}Anti-mouse CD301b (Mgl2) Monoclonal antibody (Rat, clone URA-1), PerCP-Cy5.5 conjugatedBioLegendCat\#146809; RRID:[AB_2563391](nif-antibody:AB_2563391){#intref0315}Anti-mouse CD273 (PD-L2) Monoclonal antibody (Rat, clone TY25), BUV395 conjugatedBD BiosciencesCat\#565102; RRID:[AB_2739068](nif-antibody:AB_2739068){#intref0320}Anti-mouse F4/80 Monoclonal antibody (Rat, clone BM8), BV785 conjugatedBioLegendCat\#123141; RRID:[AB_2563667](nif-antibody:AB_2563667){#intref0325}Anti-mouse CX3CR1 Monoclonal antibody (Mouse, clone SA011F11), BV785 conjugatedBioLegendCat\#149029; RRID:[AB_2565938](nif-antibody:AB_2565938){#intref0330}Anti-mouse TCR V beta 6 Monoclonal antibody (Rat, clone RR4-7), FITC conjugatedBD BiosciencesCat\#557004; RRID:[AB_647180](nif-antibody:AB_647180){#intref0335}Anti-mouse TCR V beta 12 Monoclonal antibody (Mouse, clone MR11-1) FITC conjugatedBD BiosciencesCat\#557004; RRID:[AB_647180](nif-antibody:AB_647180){#intref0340}Anti-mouse OVA IgG2c (Mouse, hybridoma clone 23-9 and 27-6)Provided by Dr. Karasuyama and ArgenxThis paper**Bacterial and Virus Strains**PVM strain J3666Gift from Andrew Easton ([@bib24], [@bib103])N/AH3N2 Influenza strain X31Medical Research Council ([@bib33], [@bib80])N/AMycobacterium smegmatis (MC2155)Malaghan Institute of Medical Research ([@bib22])N/ANippostrongylus brasiliensis L3 larvaeMalaghan Institute of Medical Research ([@bib18])N/A**Chemicals, Peptides, and Recombinant Proteins**Fc block (clone 2.4G2)BiocerosN/AStreptavidin, PE-CF594 conjugatedBD BiosciencesCat\#562284Cell proliferation dye eFl450Thermo Fisher ScientificCat\#65-0842-90β-mercaptoethanolSigma-AldrichCat\#3148DNase IRocheCat\#04 536 282 001Liberase TLRocheCat\#05 401 020 001PBSGIBCOCat\#10010-015EDTAWestburgCat\#51234Fetal Bovine SerumBodincoCat\#S181GBSASigma-AldrichCat\#A8806GentamicinThermo Fisher ScientificCat\#15710-049GlutaMAXThermo Fisher ScientificCat\#35050-038MEM alphaThermo Fisher ScientificCat\#22571-020RPMIThermo Fisher ScientificCat\#21875-059FoxP3 Transcription factor staining buffer kitThermo Fisher ScientificCat\#00-5523-00OptiprepAxis ShieldCat\#1114542PVM M~37-47~ (PMFQTSLPKNS)PepscanN/APVM N~339-347~ (GAPRNRELF)PepscanN/ADer p 1 peptide (GCGSCWAFSGVAATESA\
YLAYR)PepscanN/ARecombinant Human/Mouse Flt3LVIB Protein Service FacilityN/ARecombinant Mouse GM-CSFVIB Protein Service FacilityN/ARecombinant Mouse IFNαProvided by Dr. Roosmarijn E. Vandenbroucke, VIB-Ghent University, Belgium[@bib69]Recombinant Mouse IFNγR&D systemsCat\#485-MI-100Recombinant Mouse TSLPThermo Fisher ScientificCat\#14-8498-80Recombinant Mouse IL-33R&D systemsCat\#3626-MLRecombinant Mouse IL-25R&D systemsCat\#1399-ILUltrapure *E. coli* LPSInvivogenCat\#tlrl-3pelpsR848 (resiquimod)InvivogenCat\#tlrl-r848-5Poly(I:C) LMWInvivogenCat\#tlrl-picwCpG class B ODN1826InvivogenCat\#tlrl-1826-5AF647 Succinimidyl EsterThermo Fisher ScientificCat\#A-20006CellTracker Deep RedThermo Fisher ScientificCat\#C34565EndoFit OvalbumineInvivogenCat\#vac-povaHouse dust mite extractGreer LaboratoriesCat\#XPB82D3A2.5Beta-glucan (Candida albicans SC5314)Provided by Dr. David L. Williams, East Tennessee State University, USA[@bib43]**Critical Commercial Assays**Live/Dead eFluor 506Thermo Fisher ScientificCat\#65-0866-18Live/Dead eFluor 780Thermo Fisher ScientificCat\#65-0865-14Bio-Plex Pro Mouse Cytokine 23-plex AssayBio-Rad LaboratoriesCat\#M60009RDPDMagniSort Streptavidin negative selection beadsThermo Fisher ScientificCat\#MSNB-6002-74RNeasy Micro Plus kitQIAGENCat\#74034**Deposited Data**Murine RNA-sequencing dataThis paperGSE149619Murine Micro-array dataThis paperGSE149619**Experimental Models: Cell Lines**OP9-GFPGift from Tom Taghon[@bib106]**Experimental Models: Organisms/Strains**Mouse: C57BL/6j SPFJanvier Labs or Jackson LaboratoryN/AMouse: PVM M~37-47~ CD4 TCR TgThis paperN/AMouse: PVM N~339--347~ CD8 TCR TgThis paperN/AMouse: 1-Der: Der p 1-specific CD4 TCR TgIn house generated[@bib82]Mouse: *Irf8*^*loxP/loxP*^In house generated[@bib93]Mouse: *Irf4*^*loxP/loxP*^Provided by Dr. W. Agace, University of Lund, Sweden[@bib81]Mouse: *Fcer1g*^*−/−*^ :*B6.129P2-Fcer1g*^*tm1Rav*^*N12*TaconicModel 583Mouse: Kaede mice: *B6.Cg-Tg(CAG-tdKaede)15Utr*Provided by Dr. Tatyana Chtanova, Garvan Institute of Medical Research, Australia[@bib99]Mouse: *Ifnar1*^*−/−*^Provided by Dr. Roosmarijn E. Vandenbroucke, VIB-Ghent University, Belgium[@bib38]Mouse: *Ccr2*^*−/−*^:*B6(C)-Ccr2*^*tm1.1Cln*^*/J*Jackson LaboratoriesStock No: 027619Mouse: *Flt3L*^*−/−*^:*C57BL/6-Flt3l*^*tm1Imx*^*/TacMmjax*Jackson LaboratoriesStock No: 37395Mouse: *Itgax-cre*:*B6.Cg-Tg(Itgax-cre)1-1Reiz/J*Jackson LaboratoriesStock No: 008068Mouse: CD45.1:*B6.SJL-Ptprc*^*a*^*Pepc*^*b*^*/BoyJ*Jackson LaboratoriesStock No: 002014Mouse: *Csf2rb*^*−/−*^: *B6.129S1-Csf2rb*^*tm1Cgb*^*/J*Jackson LaboratoriesStock No: 005940Mouse: *Fcer1a*^*−/−*^:*B6.C.129S2-Fcer1a*^*tm1Knt*^*/J*Jackson LaboratoriesStock No: 005629**Software and Algorithms**FlowJo v11FlowJo<https://www.flowjo.com>GraphPad Prism 7GraphPad Software<https://www.graphpad.com>; RRID: [SCR_002798](rridsoftware:SCR_002798){#intref0355}Ingenuity Pathway AnalysisQIAGEN Bioinformatics<https://www.qiagenbioinformatics.com/products/ingenuity-pathway-analysis/>Adobe IllustratorAdobe<https://www.adobe.com/>
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### Lead Contact and Materials Availability {#sec5.2.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Bart N. Lambrecht (<bart.lambrecht@ugent.be>).

### Data and Code Availability {#sec5.2.2}

Cell type-specific expression patterns of individual genes together with the gene-barcode matrices and annotation matrices can be accessed via an online browser tool (<http://bioit2.irc.ugent.be/cdc2/>). The accession number for the raw RNA-sequencing data reported in this paper is GSE149619.

Experimental Model and Subject Details {#sec5.3}
--------------------------------------

### *In vivo* Animal Studies {#sec5.3.1}

The following mice were used in this study; female C57BL/6 mice (aged 6-10 weeks) were purchased from Janvier (France). *Fcer1g* ^−/−^ mice were purchased from Taconic (USA). PVM M~37-47~ CD4^+^ and N~339--347~ specific CD8^+^ TCR transgenic mice were generated in house ([@bib103], [@bib104], [@bib107]) ([Figure S2](#mmc1){ref-type="supplementary-material"}). CD45.1, CD45.1.2, Der p 1-specific (1-Der) CD4^+^ TCR Tg, PVM CD4^+^ TCR Tg *Rag2* ^*−/−*^, PVM CD8^+^ PVM TCR Tg *Rag2* ^*−/−*^, *FcεRIa* ^*−/−*^, *Ccr2* ^*−/−*^ *, Flt3l* ^*−/−*^ *, Csf2rb* ^*-/*^ *,* ^*-*^ *Irf4* ^*fl/fl*^ and *Irf8* ^*fl/fl*^ *Itgax*-*cre* mice ([@bib20], [@bib81], [@bib82], [@bib93]) were bred in house in specific pathogen-free conditions at the animal facility of Ghent University. *Itgax*-*cre* mice with germline deletion were detected by PCR and excluded from further analysis. *Ifnar1* ^*−/−*^ mice were kindly donated by Prof. Dr. Roos Vandenbroucke ([@bib38]). Mice for the Ms and Nb skin infection models were bred and housed at the Malaghan Institute of Medical Research animal facility under specific pathogen-free conditions and age- and sex-matched mice were used within experiments. C57BL/6J were originally obtained from the Jackson Laboratory (Bar Harbor, ME). B6.Cg-Tg(CAG-tdKaede)15Utr mice ([@bib4], [@bib99]) were bred from pairs obtained from Dr. Tatyana Chtanova (Garvan Institute of Medical Research, Australia). All experiments were approved by the independent animal ethical committee "Ethische Commissie Dierproeven -- faculteit Geneeskunde en Gezondheids-wetenschappen Universiteit Gent." Experimental protocols for the Ms and Nb skin infection models were approved by the Victoria University of Wellington Animal Ethics Committee and performed in accordance with institutional guidelines.

### Generation of MHC class I-restricted, N339-347 and MHC class II-restricted, M37-47 PVM-specific TCR transgenic mice {#sec5.3.2}

The generation of the PVM-TCR transgenic mice was done as described recently ([@bib104]). Briefly, splenocytes retrieved from C57BL/6 mice 16 days after sublethal i.t. infection (35 pfu) with PVM (J3666 strain), were depleted for either CD8^+^ or CD4^+^ cells through negative selection by MACS, and then restimulated with either the CD4^+^ or CD8^+^ immunodominant PVM epitope corresponding to amino acids 37-47 in the matrix protein (M37-47) ([@bib103]) or 339-347 in the nucleoprotein (N339-347) ([@bib107]) respectively. Next, CD4^+^ or CD8^+^ cells were positively selected by MACS from these enriched cell pools and immortalized by fusion with BW5147 cells. From specificity-selected monoclonal T cell clones (IL2^+^CD69^+^ in DC:T cell co-culture), the Vα and Vβ of the CD4^+^ TCR were subcloned in the p783 (containing a transcriptional CD8^+^ silencer element) and p428 expression vector respectively. For the CD8^+^ TCR both the Vα and Vβ were subcloned in the p428 expression vector. The TCR constructs were micro-injected in fertilized *Rag2* ^*−/−*^ oocytes. Validation of the TCR transgenic mice was done by genotyping using primers from the TCR PCR panel corresponding to the construct (TCR Vα and Vβ), analysis of T cells in peripheral blood ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2E) and *in vitro* evaluation of TCR specificity in a DC-T cell co-culture ([Figures S2](#mmc1){ref-type="supplementary-material"}A and S2D). Finally, adoptive transfer of TCR transgenic T cells into PVM infected wild-type acceptor mice provided *in vivo* validation ([Figures S2](#mmc1){ref-type="supplementary-material"}C and S2F).

Method Details {#sec5.4}
--------------

### BM Chimeric Mice {#sec5.4.1}

BM was prepared by crushing femurs and tibias in phosphate buffer saline (PBS) followed by filtering through a sterile 70 μm cell strainer. BM cells were suspended in RPMI-1640 medium (Sigma-Aldrich) supplemented with 50% FCS and 10% DMSO (Sigma-Aldrich) and stored at −150°C. BM chimeras were generated by lethally irradiating (8 Gy dose) CD45.2^+^ or CD45.1.2^+^ C57BL/6 female recipient mice aged 6-8 weeks. Five hours later, mice received 2 x 10^6^ mixed BM cells of gender- and age-matched CD45.1^+^ WT and CD45.2^+^ transgenic donor mice (either *Csf2rb* ^*−/−*^, *Ccr2* ^*−/−*^, *Irf8* ^*fl/fl*^ *Itgax*-*cre* ^Tg^, *Irf8* ^*fl/fl*^ *Itgax*-*cre* ^Wt^ or *Ifnar1* ^*−/−*^), at a 50-50 ratio. Chimeric mice were subjected to infection 12 weeks upon reconstitution.

### Infection, immunizations and *in vivo* treatments {#sec5.4.2}

Mice were anesthetized with isoflurane (2 l/min, 2%--3%) and infected intranasally with 10^5^ TCID~50~ H3N2 X31 influenza A virus or mock virus (allantoic fluid of uninfected eggs); all diluted in 50 μl PBS ([@bib33], [@bib80]). Mouse-passaged stocks of PVM strain J3666 were grown as described ([@bib24]). Anesthetized mice were infected intratracheally with a previously *in vivo* titrated sub-lethal dose of 35 pfu PVM virus (J3666) diluted in 80 μl PBS ([@bib103]). Weight loss was monitored daily. For HDM (Greer Laboratories) experiments, 100 μg HDM diluted in 80 μl PBS was administered i.t. as described previously ([@bib82]) or 75 μg HDM (Greer Laboratories, USA) in combination with 300 ng LPS (Invivogen) and beta-glucans (Provided by Dr. David L. Williams ([@bib43])).

For skin immunizations, mice were anesthetized and injected intradermally (i.d.) with 4x10^6^ CFU heat-killed Ms ([@bib22]) or 300 non-viable Nb into the ear pinna ([@bib18]). For photoconversion experiments, mice were anesthetized and each side of the ear was exposed to a 130mV 405nm violet laser for 10 s, while all other parts of the head were protected by a face shield. Immediately after photoconversion, fluorescently labeled antigens were injected intradermally as mentioned before.

### Preparation of immunogens {#sec5.4.3}

M. smegmatis (Ms, mc2155) was grown in Luria-Bertani broth overnight at 37°C. Bacteria were washed three times in PBS containing 0.05% Tween 80 and heat-killed at 75°C for 1 hour. N. brasiliensis (Nb) infective L3 larvae were prepared, washed in sterile PBS and killed by three freeze-thaw cycles as described ([@bib18]). For fluorescent labeling of pathogens, non-viable Ms or Nb were labeled with CellTrace™ Far Red (ThermoFisher Scientific) according to the manufacturer's instructions.

### Immune serum transfer {#sec5.4.4}

Whole blood from 8-10 weeks old PVM convalescent female C57BL/6 mice was obtained at 15dpi with 35 pfu or from mock infected controls by terminal bleeding. Whole blood was allowed to clot at room temperature (RT) for 30 minutes, then centrifuged for 10 minutes at 1000 g at RT. Next, collected serum was heat-inactivated at 56°C for 30 minutes and stored at −20°C. Serum was diluted 1:2 in PBS (ThermoFisher Scientific) and administered i.t. in a volume of 80 μl at 6dpi with PVM.

### OVA and OVA immune complexes {#sec5.4.5}

Ovalbumine (Invivogen) was fluorescently labeled with AF647 Succinimidyl Ester (ThermoFisher Scientific) according to the manufacturer's instructions. Immune complexes were pre-formed at RT for 30 minutes by using 2 different monoclonal anti-OVA IgG2c antibodies in a 1:1 molar ratio with OVA-AF647. For the anti-OVA IgG2c antibodies, mRNA from hybridomas (clone 23-9 and 27-6; mIgG1) gifted by Dr. H. Karasuyama, was reverse transcribed and variable domains were amplified, sequenced and recloned in mouse IgG2c constant domains. HEK293-E produced antibodies were purified using MabSelectSure LX affinity and Superdex 200 gelfiltration (GE Life Sciences). At 6dpi with PVM, 50μg OVA-AF647 alone or as an immune complex was administered i.t. in a volume of 80 μl PBS.

### Flt3L Bone marrow cultures {#sec5.4.6}

Single BM cell suspensions were suspended in tissue culture medium (TCM; RPMI-1640 medium (Thermo Fisher Scientific) containing 10% fetal calf serum (FCS, Bodinco), 1.1 mg/ml β-Mercaptoethanol (Sigma-Aldrich), 2 mM L-alanyl-L-glutamine dipeptide (Thermo Fisher Scientific) and 56 μg/ml Gentamicin (Thermo Fisher) Scientific) supplemented with 250 ng/ml Flt3L (PSF, VIB Protein Service Facility). Cells were plated at 2x10^6^ cells per well in 2 ml of TCM in 24-well plates and cultured at 37°C in a humidified atmosphere at 5% CO~2~ and kept for 3 days. OP9 cells were cultured in OP9 culture medium (MEMα medium (Thermo Fisher) containing 20% FCS (Bodinco), 2 mM L-alanyl-L-glutamine dipeptide (Thermo Fisher Scientific) and 56 μg/ml Gentamicin (Thermo Fisher Scientific)) ([@bib106]). On day 3 of differentiation, half of the volume (i.e., 1 ml) of BM cells in TCM was transferred to a single well containing a monolayer of OP9 cells in 1ml fresh OP9 medium supplemented with 250 ng/ml Flt3L in 24-well plates ([@bib54]). On day 8 of differentiation, half of the medium was refreshed (i.e., 1ml 50:50 OP9:TCM medium with 250 ng/ml Flt3L) and supplemented with LPS (200 ng/ml; Invivogen), Poly (I:C) (1000 ng/ml; Invivogen), R848 (1000 mg/ml; Invivogen,), CpG (100 ng/ml; Invivogen), IFNα (200 ng/ml; Donated by Prof. Dr. Vandenbroucke ([@bib69])), IFNγ (200 ng/ml; R&D systems), GM-CSF (300 ng/ml; PSF, VIB Protein Service Facility), IL-33 (200 ng/ml; R&D systems), TSLP (200 ng/ml; Thermo Fisher Scientific) and IL-25 (200 ng/ml; R&D systems). For OVA-uptake assay 10 μg/ml OVA-AF647 either alone or as IC was added immediately after adding the stimuli. The cultures were harvested 20h later.

### Tissue sampling and processing {#sec5.4.7}

Mice were sacrificed at time points indicated by intraperitoneal (i.p.) injection of sodium pentobarbital. The lungs were then mechanically disrupted by GentleMACS dissociation (Miltenyi Biotec) (Lung program 01_01) in 3 ml RPMI 1640 (GIBCO) containing 20 μg/ml Liberase and 10 U/ml Dnase (Roche), followed by digestion for 30 min at 37°C and final GentleMacs homogenization (Lung program 02_01). Single cell suspensions were prepared by digestion in collagenase/DNase (Roche) solution; lungs were digested for 30 minutes at 37°C, MLNs were digested 15 minutes at 37°C. Next, the cell suspension was passed through a 100 μm filter and red blood cells were lysed using ammonium chloride lysis buffer (10 mM KHCO3, 155 mM NH4Cl, 0,1 mM EDTA in MilliQ water). Auricular LNs were digested with 100μg/ml Liberase TL and 100μg/ml DNase I (Roche) for 30 minutes at 37°C before passing through a 70 μm cell strainer.

### Flow cytometry and cell sorting {#sec5.4.8}

Single cell suspensions were incubated with a mix of fluorescently labeled monoclonal antibodies (Ab) for 30 minutes at 4°C. To reduce non-specific binding, 2.4G2 Fc receptor Ab was added. Dead cells were removed from analysis, using fixable viability dye eFluor506 (eBioscience). For intracellular staining, cells were fixed using a fixation/permeabilization kit (Thermo Fisher Scientific) according to the manufacturer's protocol. For cell restimulation, 5 x 10^6^ cells were incubated with 1 ml 1x Cell Stimulation Cocktail (eBioscience) for 6h at 37°C and fixed using a fixation/permeabilization kit (Thermo Fisher Scientific). In order to monitor individual cell divisions of the T cells, cells were stained with Cell proliferation dye eFl450 (CTV, Thermo Fisher Scientific) according to the manufacturer's protocol.

Before acquisition, photomultiplier tube voltages were adjusted to minimize fluorescence spillover. Single-stain controls were prepared with UltraComp eBeads (Thermo Fisher Scientific) following the manufacturer's instructions, and were used to calculate a compensation matrix. Sample acquisition was performed on a LSR Fortessa or FACSymphony cytometer equipped with FACSDiva software (BD biosciences). Final analysis and graphical output were performed using FlowJo software (Tree Star, Inc.) and GraphPad Prism 6 (GraphPad Software, Inc.). For sorting of DC subsets and T cells, cells were stained as described and cell sorting was performed on a FACSAria II and III (BD biosciences).

### Pre-cDC transfer {#sec5.4.9}

Pre-cDC transfer was done as previously described ([@bib89]). Briefly, to expand pre-cDCs, CD45.2 wild-type mice were injected every other day with 10 μg Flt3L (PSF, VIB). Mice were killed 8 days after the first treatment and bone marrow was isolated. Red blood cells were lysed by ammonium chloride osmotic lysis buffer. Cells were labeled with eFl450 cell proliferation dye (Thermo Fisher Scientific) and pre-cDCs were sorted as CD45+, Lin- (CD3, CD19, MHC II, CD49b, CD11b, B220), CD11c^int^, Sirpα^int^. 8 × 10^5^ cells were injected i.v. into CD45.1/2 wild-type mice 1dpi. Lung and MLN cells were analyzed 4 days later (5dpi).

### Monocyte transfer {#sec5.4.10}

Monocyte transfer was done as previously described ([@bib7]). Bone marrow cells were isolated from CD45.1 wild-type mice. Red blood cells were lysed by using osmotic lysis buffer. Cells were labeled with eFl450 cell proliferation dye (CTV, Thermo Fisher Scientific) and monocytes were sorted as Lin- (CD3, CD19, MHCII, SiglecF, Ly6G), CD11c-, c-kit-, CD11b^hi^ and Ly6C^hi^. 8 × 10^5^ cells were injected i.v. into CD45.2 *Ccr2* ^−/−^ mice 1dpi. Lung and MLN cells were analyzed 4 days later (5dpi).

### DC--CD4^+^ and CD8^+^ T cell co-culture {#sec5.4.11}

Migratory DCs harvested from the MLN and lung 8 dpi with PVM or 72h after challenge with HDM, LPS and beta-glucans, were enriched by gradient selection ([@bib14]) and sorted by distinct subset. Naive CD44^-^CD62L^+^Lin^-^(CD11c, MHCII, CD19) CD4^+^ and CD8^+^ T cells specific for the H2-IA^b^-restricted M~37-47~ ([@bib103]) and the H-2^b^-restricted N~339--347~ ([@bib107]) PVM-epitope respectively or H2-IA^b^-restricted Der p 1 peptide ([@bib82]), were isolated and sorted from spleens and LN of *Rag2* ^*−/−*^ TCR Tg mice and labeled with Cell proliferation dye eFluor450 (CTV, Thermo Fisher Scientific) according to the manufacturer's instructions. 5000 sorted DCs were co-cultured with sorted T cells in a 1:10 DC:T cell ratio in sterile tissue culture medium (TCM; RPMI (GIBCO) containing 10% fetal calf serum (Bodinco), 1.1 mg/ml β-Mercaptoethanol (Sigma-Aldrich), 2 mM L-alanyl-L-glutamine dipeptide (Thermo Fisher Scientific) and 56 μg/ml Gentamicin (Thermo Fisher Scientific)) on ice. CTV dilution and T cell activation were evaluated by flow cytometry after 4 days of incubation at 37°C, 5% CO~2~ and 20% O~2~. For peptide controls, 5 μg/ml PVM M~37-47~, 1 ug/ml PVM N~339-347~ or (Pepscan) or 5 ug/ml Der p 1 peptide (Pepscan) were added to the cultures. Cytokine production by the PVM-specific or 1-Der T cells was measured in a Bio-Plex system (Biorad) on the co-culture supernatants.

### Micro-array {#sec5.4.12}

10000 cells of each of the DC subsets were isolated from the lung and MLN 4dpi as described above. RNA was obtained with an RNEasy Plus Micro Kit according to the manufacturer's instructions (QIAGEN) and RNA integrity was assessed with a Bioanalyser 2100 (Agilent). With a WT Expression Kit (Ambion) 50 ng of total RNA per sample 'spiked' with bacterial poly(A) RNA positive control (Affymetrix) was converted to double-stranded cDNA in a reverse-transcription reaction. Samples were fragmented and labeled with biotin in a terminal labeling reaction according to the Affymetrix WT Terminal Labeling Kit. A mixture of fragmented biotinylated cDNA and hybridization controls (Affymetrix) was hybridized on a GeneChip Mouse Gene 1.0 ST Array (Affymetrix), followed by staining and washing in a GeneChip fluidics station 450 according to the manufacturer's procedures (Affymetrix). For analysis of raw probe signal intensities, chips were scanned with a GeneChip scanner 3000 (Affymetrix). Samples were subsequently analyzed with software of the R project for statistical computing (Bioconductor). All samples passed quality control, and the robust multiarray average procedure was used for normalization of data within arrays (probe-set summarization, background correction and log2 transformation) and between arrays (quantile normalization). In a subsequent step, probe sets that either mapped to multiple genes or had low variance were filtered out. The final analysis of the obtained data was performed by using Ingenuity Pathway Analysis (IPA, QIAGEN).

### Single Cell RNA Sequencing {#sec5.4.13}

#### Sorting and RNA Isolation {#sec5.4.13.1}

Single cell suspensions were obtained as described earlier from the pooled lungs of 8 WT:*Irf8* ^*fl/fl*^ *Itgax*-Cre^Tg^ or 6 WT: *Irf8* ^*fl/fl*^ *Itgax*-Cre^Wt^. chimeras at 10dpi with PVM. Prior to FACS purification, cells were stained with biotinylated CD3eCD19and Ly6G, followed by MagniSort Streptavidin negative selection beads. Enrichment by negative selection prior to sorting was done according to the manufacturer's instructions (Thermo Fisher Scientific). 72000 SiglecF-CD3-CD19-CD11c^+^MHCII^+^ CD45.1 and CD45.2 live cells from lungs 10 dpi with PVM of WT(CD45.1):*Irf8fl/fl Itgax-Cre* ^*Tg*^(CD45.2) and control WT(CD45.1):*Irf8fl/fl Itgax-Cre* ^*Wt*^(CD45.2) chimeric mice were FACS-purified. Cells were sorted into PBS 0.04% BSA, spun down and resuspended in PBS with 0.04% BSA at an estimated final concentration of 1000 cells/μl. Cellular suspensions (target recovery of 10000 cells) were loaded on a GemCode Single-Cell Instrument (10x Genomics, Pleasanton) to generate single-cell Gel Bead-in-EMulsion (GEMs). Single-cell RNA-Seq libraries were prepared using GemCode Single-Cell 3ʹGel Bead and Library Kit (10x Genomics) according to the manufacturer's instructions and as previously described ([@bib90]).

#### Single Cell RNA Sequencing Analysis {#sec5.4.13.2}

Sequencing libraries were loaded on an HiSeq4000 (Illumina, San Diego, Ca) with custom sequencing settings (28/8/0/98 - 2.1pM loading concentration). Sequencing was performed at the VIB Nucleomics Core (VIB, Leuven). Demultiplexing of the raw data and mapping to the mouse genome mm10 was done by the 10X CellRanger software (version 2.0.0 and version 2.0.2; cellranger). The aggregation of the WT (CD45.1) and transgenic (CD45.2 either Irf8fl/fl Itgax-Cre^Tg^ or Itgax-Cre^Wt^) samples was done using 'cellranger aggr' (10x's CellRanger software).

#### Preprocessing Data {#sec5.4.13.3}

Preprocessing of the data was done by the scran and scater R package according to workflow proposed by the Marioni lab ([@bib67]). Outlier cells were identified based on 3 metrics (library size, number of expressed genes and mitochondrial proportion) and cells were tagged as outliers when they were 3 median absolute deviation (MADs) away from the median value of each metric across all cells. Detecting highly variable genes, finding clusters and creating tSNE plots was done using the Seurat pipeline. Marker genes per identified subpopulation were found using the findMarker function of the Seurat pipeline. Additional low quality (low UMI counts, high % of mitochondrial genes) and contaminating cells (potential doublets, lymphocytes, non-immune cells) were also removed from the analysis ([Figure S4](#mmc1){ref-type="supplementary-material"}A).

#### Single-cell regulatory network inference and clustering using SCENIC {#sec5.4.13.4}

We performed SCENIC ([@bib1]) by starting from the raw counts and following the proposed workflow using the default parameters. The co-expression network was generated using GENIE3 rather than GRNBoost2. AUC, which identifies and scores gene regulatory networks or regulons in single cells, was calculated using AUCell as previously described ([@bib1]). The better the targets of a regulon match the highly expressed genes of a certain cell, the higher the AUC value of that regulon in that particular cell.

Quantification and Statistical Analysis {#sec5.5}
---------------------------------------

In all experiments, data are presented as mean ± SEM. Statistical tests were selected based on appropriate assumptions with respect to data distribution and variance characteristics. One-way ANOVA with Sidak correction for multiple testing was used for the statistical analysis of differences between more than two groups. Two-way ANOVA with Sidak post-test was used for the statistical analysis of differences between more than two groups and with 2 different independent variables. Statistical significance was defined as p \< 0.05. Sample sizes were chosen according to standard guidelines. Number of animals is indicated as ''n.'' Of note, sizes of the tested animal groups were also dictated by availability of the transgenic strains and litter sizes, allowing littermate controls. Statistical details of experiments can be found in the figure legends. The investigator was not blinded to the mouse group allocation.
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